Investigation of the immune-modulatory effects of erythromycin by Fernandes, Antonio, Celestino
INVESTIGATION OF
THE IMMUNE-MODULATORY EFFECTS OF 
ERYTHROMYCIN
by
ANTONIO CELESTINO FERNANDES
A Dissertation submitted to the Faculty 
of Medicine, University of the 
Witwatersrand, Johannesburg, for the 
Degree of Master of Science (MED).
JOHANNESBURG, 1986
DECLARATION
This is to certify that the dissertation "INVESTIGATION 
OF THE IMMUNE-MODULATORY EFFECTS OF ERYTHROMYCIN" 
presented for the degree of Master of Science (MED) at 
the University of the Witwatersrand, Johannesburg, is 
my own work and has not been presented at any other 
University.
Parts of this dissertation have been published in the 
following papers:-
1. Studies on the effects of ingestion of a single 
500 mg. oral dose of erythromycin stearate on leucocyte 
motility and transformation and on release in-vitro of 
prostaglandin E2 by stimulated leucocytes.
R. Anderson, A.C. Fernandes and H.E. Eftychis.
Journal of Antimicrobial Chemotherapy, 14, 41-50, 1984.
2. Enhancement of human polymorphonuclear leucocyte 
motility by erythromycin in-vitro and in-vivo.
A.C. Fernandes, R. Anderson, A.J. Theron, G. Joone, 
C.E.J. van Rensburg.
South African Medical Journal, 66, 173-177, 1984.
ANTONIO CELESTINO FERNANDES
I
3 An objective filter-based, enzymatic method for 
the in-vivo measurement of the migration of human
polymorphonuclear leucocytes.
A.C. Fernandes, R. Anderson and G.J. Ras.
Journal of Immunological Methods, 83, 259-271, 1985.
II
ACKNOWLEDGEMENTS
I would like to express my thanks and gratitude to the 
following people:
Prof. H.J. Koornhof of the Microbiology 
Department, South African Institute for Medical 
Research and School of Pathology, University of 
the Witwatersrand, Johannesburg, for his interest 
and advice.
Prof. R. Anderson of the Microbiology Department, 
Immunology Unit, Institute of Pathology, 
University of Pretoria, for his advice and 
encouragement.
Prof. A.J. van Rensburg for allowing the free use 
of the facilities of the Institute of Pathology, 
University of Pretoria.
Miss. H.E. Eftychis for the technical advice 
offered.
My wife for her encouragement and support.
Ill
LIST OF FIGURES
FIGURE PAGE
1. STRUCTURES OF THE FOUR ERYTHROMYCINS. ... 2
2. PHOTOGRAPH OF THE SUCTION BLISTER
APPARATUS...............................  50
3. PHOTOGRAPHS OF A TYPICAL BLISTER AND THE
DIFFERENT MANIPULATIVE STAGES.............53
4. DEMONSTRATION OF THE LINEAR CFU/OD
RELATIONSHIP OF E. cloacae................59
5. DEMONSTRATION OF THE LINEAR CFU/OD
RELATIONSHIP t)F C. albicans.............  60
6. • DETERMINATION OF THE EFFECT OF BENZYL
ALCOHOL ON THE SURVIVAL RATE OF MICE 
INOCULATED WITH A LETHAL DOSE OF 
C. albicans.............................  66
7. MICE INOCULATED INTRAPERITONEALLY WITH
ERYTHROMYCIN LACTOBIONATE AND CHALLENGED 
WITH A LD50 INOCULUM OF C. albicans...... 67
8. MICE INOCULATED INTRAPERITONEALLY WITH
ERYTHROMYCIN LACTOBIONATE AND CHALLENGED 
WITH A LD100 INOCULUM OF C. albicans. __ 68
IV
9. MICE INOCULATED INTRAPERITONEALLY WITH
ERYTHROMYCIN LACTOBIONATE AND CHALLENGED 
WITH A LD100 INOCULUM OF C. albicans 
(DOSE RESPONSE SHOWN)...................  69
10a-d. THE EFFECTS OF INTRAVENOUS ADMINISTRATION
Of ERYTHROMYCIN LACTOBIONATE ON THE SURVIVAL 
RATE OF MICE INOCULATED WITH A LETHAL 
INTRAPERITONEAL INOCULUM OF C. albicans. 71
11. PMNL ACCUMULATION IN NITROCELLULOSE
FILTERS.................................  86
12. PMNL ACCUMULATION, MEASURED BY MPO
RELEASE, WITH VARIOUS FMLP
CONCENTRATIONS..........................  87
13. KINETICS OF PMNL ACCUMULATION ON DOUBLE
FILTERS ACCORDING TO MPO AND LYSOZYME 
RELEASE.................................  90
V
LIST OF TABLES
TABLE PAGE
1. THE DETERMINATION OF MIC AND MCC OF ERYTHROMYCIN
FOR E. cloacae AND C. albicans.............  58
2. THE EFFECT OF ERYTHROMYCIN ON THE IN-VITRO GROWTH
RATE OF C. albicans IN THE PRESENCE OF 
ERYTHROMYCIN USING A TURBIDOMETRIC METHOD........61
3. THE EFFECT OF ERYTHROMYCIN ON THE IN-VITRO
GROWTH RATE OF E. cloacae IN THE PRESENCE OF 
ERYTHROMYCIN USING A TURBIDOMETRIC METHOD........62
4. DETERMINATION OF THE QUANTITY OF ERYTHROMYCIN
LACTOBIONATE IN THE PERITONEUM OF MICE AT 
DIFFERENT TIME INTERVALS AFTER INTRAPERITONEAL 
INOCULATION OF ERYTHROMYCIN LACTOBIONATE........64
5. STATISTICAL ANALYSIS OF FIGURES 10a, 10b, 10c and
10d.........................................  72
6. PHA-INDUCED TRANSFORMATIONS OF MOUSE SPLEEN 
LYMPHOCYTES; MICE WERE PRE-INOCULATED 
INTRAPERITONEALLY WITH ERYTHROMYCIN
LACTOBIONATE 2 HOURS PRIOR TO SACRIFICE......... 73
7. CON-A INDUCED TRANSFORMATIONS OF MOUSE SPLEEN 
LYMPHOCYTES; MICE WERE PRE-INOCULATED 
INTRAPERITONEALLY WITH ERYTHROMYCIN
LACTOBIONATE 2 HOURS PRIOR TO SACRIFICE......... 74
VI
8. PHA-INDUCED TRANSFORMATION OF MOUSE SPLEEN 
LYMPHOCYTES; MICE WERE PRE-INOCULATED 
INTRAVENOUSLY WITH ERYTHROMYCIN
LACTOBIONATE 2 HOURS PRIOR TO SACRIFICE........76
9. CON-A INDUCED TRANSFORMATION OF MOUSE SPLEEN 
LYMPHOCYTES; MICE WERE PRE-INOCULATED 
INTRAVENOUSLY WITH ERYTHROMYCIN
LACTOBIONATE 2 HOURS PRIOR TO SACRIFICE........77
10. THE EFFECT ON THE RATE OF % PHAGOCYTIC UPTAKE BY 
PMNL OF C. albicans PREVIOUSLY EXPOSED TO 
ERYTHROMYCIN...................................  79
11 THE EFFECT OF THE ADMINISTRATION OF 
ERYTHROMYCIN STEARATE ON PHA INDUCED 
TRANSFORMATION OF HUMAN LYMPHOCYTES
CONTAINED IN WHOLE BLOOD.......................  81
12 THE EFFECT OF THE ADMINISTRATION OF 
ERYTHROMYCIN STEARATE ON CON-A INDUCED 
TRANSFORMATION OF HUMAN LYMPHOCYTES
CONTAINED IN WHOLE BLOOD.......................  82
13. THE EFFECT OF THERAPEUTIC CONCENTRATONS OF
ERYTHROMYCIN ON THE MIGRATION OF HUMAN PMNLS IN 
VITRO..........................................  83
VII
14. INVESTIGATION OF THE REQUIREMENT FOR TRITON-X 100
TO DETECT PMNL ACCUMULATION....................  89
15. THE EFFECTS OF ORAL ADMINISTRATION OF ERYTHROMYCIN 
ON THE IN-VIVO MIGRATION OF PMNLs..............  93
VIII
LIST OF CONTENTS
Page
ACKNOWLEDGEMENTS...................................  Ill
LIST OF FIGURES....................................  IV
LIST OF TABLES...............................   VI
SUMMARY............................................  XVI
CHAPTER I. LITERATURE REVIEW.
LITERATURE REVIEW...................................  1
THE DIRECT ANTIBIOTIC EFFECT OF ERYTHROMYCIN ON THE 
MICROBIAL PATHOGEN.
Erythromycin...................................  2
Mode of action.................................  3
Toxicity.......................................  4
INDIRECT ANTIBIOTIC EFFECT ON THE INFECTIVE MICRO­
ORGANISMS DUE TO ANTIBIOTIC MEDIATED CHANGES........  5
BACTERIAL INHIBITION OF THE HOST'S IMMUNOLOGICAL 
DEFENCE MECHANISMS..................................  6
THE ACHIEVEMENT OF ADEQUATE SERUM ANTIBIOTIC LEVELS. 7
THE FAILURE OF THE IMMUNE SYSTEM TO NEUTRALIZE 
INTRACELLULAR PATHOGENS.............................  7
THE ABILITY OF ANTIBIOTICS TO CROSS BIOLOGICAL 
MEMBRANES...........................................  9
DECLARATION............................................  I
IX
ANTIBIOTIC/IMMUNE SYSTEM INTERACTION................  12
Antibiotic effects on chemotaxis...............  15
Antibiotic effects on phagocytosis.............  17
Antibiotic effects on lymphocyte transformation. 18 
Antagonistic antibiotic effects on antibodies. . 19
Enhancing antibiotic effects on antibodies...... 19
Antagonistic antibiotic effects on complement. . 20 
Antibiotic effectiveness associated with a 
general suppression of the immune system........ 20
PATHOGENICITY OF C. albicans........................  22
RATIONALE FOR THIS STUDY............................  25
CHAPTER II. REAGENTS AND METHODS.
REAGENTS............................................  26
INSTRUMENTATION.....................................  30
EXPERIMENTAL ANIMALS................................  31
TEST ORGANISMS......................................  31
DETERMINATION OF THE MINIMUM INHIBITORY
CONCENTRATION AND MINIMUM ClDAL CONCENTRATION OF
E. cloacae AND C. albicans. ........................  32
DETERMINATION OF COLONY FORMING UNITS RELATIVE TO 
TO OPTICAL DENSITY OF E. cloacae AND C. albicans. ... 32
X
PREPARATION OF THE C. albicsns INOCULUM.............  33
INOCULUM CONCENTRATIONS OF MICRO-ORGANISMS USED.
C. albicans....................................  33
E. cloacae. ...................................  34
DETERMINATION OF THE EFFECTS OF ERYTHROMYCIN ON 
THE IN-VITRO GROWTH RATE OF C. albicans AND 
E. cloacae USING A TURBIDOMETRIC METHOD.
C. albicans.....................................  34
E. cloacae......................................  35
ASSESSMENT OF THE SUITABILITY OF E. cloacae.......... 35
MEASUREMENT OF ERYTHROMYCIN LACTOBIONATE IN THE 
PERITONEUM OF MICE, AT VARIOUS TIME INTERVALS AFTER 
INTRAPERITONEAL INOCULATION.........................  35
DETERMINATION OF THE TOXICITY OF ERYTHROMYCIN 
LACTOBIONATE INOCULATED INTRAPERITONEALLY INTO MICE. 36
INVESTIGATION OF THE EFFECT OF BENZYL ALCOHOL 
(PRESENT AS A PRESERVATIVE IN ERYTHROMYCIN 
LACTOBIONATE) ON THE SURVIVAL RATE OF MICE 
INOCULATED WITH C. albicans. .......................  36
THE EFFECT OF ERYTHROMYCIN LACTOBIONATE ADMINISTRATION 
ON THE SURVIVAL RATE OF MICE INFECTED WITH A LETHAL 
INTRAPERITONEAL INOCULUM OF C. albicans.............  37
PREPARATION OF THE E ♦ cloacae INOCULUM............... 33
XI
THE EFFECTS OF PRE-INOCULATION WITH ERYTHROMYCIN 
LACTOBIONATE ON MITOGEN INDUCED MOUSE SPLEEN 
LYMPHOCYTE TRANSFORMATION...........................  38
MOUSE AIR BLEB METHOD TO EVALUATE THE IN-VIVO 
MIGRATION RATE OF POLYMORPHONUCLEAR LEUCOCYTES....... 40
PREPARATION OF HUMAN PMNL SUSPENSION................  41
THE EFFECT ON THE RATE OF % PHAGOCYTIC UPTAKE BY 
PMNLs, OF C. albicans PREVIOUSLY EXPOSED TO 
ERYTHROMYCIN........................................  42
THE EFFECT OF ERYTHROMYCIN BASE ON INTRA-CELLULAR 
KILLING OF YEASTS BY HUMAN POLYMORPHONUCLEAR LEUCOCYTES 
IN-VITRO............................................  44
THE EFFECT OF ERYTHROMYCIN ON MITOGEN INDUCED 
TRANSFORMATION OF HUMAN BLOOD LYMPHOCYTES, USING A 
WHOLE-BLOOD METHOD..................................  4 5
THE EFFECTS OF THERAPEUTIC CONCENTRATIONS OF 
ERYTHROMYCIN ON THE MIGRATION OF HUMAN PMNLs 
IN-VITRO............................................  46
AN OBJECTIVE FILTER BASED, ENZYMATIC METHOD FOR THE 
IN-VIVO MEASUREMENT OF THE MIGRATION OF HUMAN 
POLYMORPHONUCLEAR LEUCOCYTES........................  48
XII
THE HUMAN IN-VIVO MIGRATION OF HUMAN PMNLs USING
THE ABOVE METHOD....................................  56
EXPRESSION AND STATISTICAL ANALYSES OF RESULTS...... 56
CHAPTER III. RESULTS.
THE DETERMINATION OF MINIMUM INHIBITORY
CONCENTRATION AND MINIMUM ClDAL CONCENTRATION
OF ERYTHROMYCIN FOR E. cloacae AND C. albicans........ 57
THE RELATIONSHIP OF OPTICAL DENSITY TO COLONY FORMING 
UNITS................................................ 57
THE EFFECTS OF ERYTHROMYCIN ON THE IN-VITRO GROWTH 
RATE OF E. cloacae AND C. albicans IN THE PRESENCE 
OF ERYTHROMYCIN USING A TURBIDOMETRIC METHOD......... 57
DETERMINATION OF THE QUANTITY OF ERYTHROMYCIN 
LACTOBIONATE IN THE PERITONEUM OF MICE AFTER 
AN INTRAPERITONEAL INOCULATION OF ERYTHROMYCIN 
LACTOBIONATE........................................  63
DETERMINATION OF THE TOXICITY OF ERYTHROMYCIN 
LACTOBIONATE TO MICE WHEN INOCULATED
I NTRAPERI TONE ALLY...................................  63
DETERMINATION OF THE EFFECT OF BENZYL ALCOHOL ON THE 
SURVIVAL RATE OF MICE INOCULATED WITH C. albicans. .. 65
THE EFFECT OF ORAL ADMINISTRATION OF ERYTHROMYCIN ON
XIII
THE EFFECT OF INTRAPERITONEAL ADMINISTRATION OF 
ERYTHROMYCIN LACTOBIONATE ON THE SURVIVAL RATE OF 
MICE INOCULATED WITH A LETHAL INTRAPERITONEAL 
INOCULUM OF C. albicans.............................  65
THE EFFECT OF INTRAVENOUS ADMINISTRATION OF 
ERYTHROMYCIN LACTOBIONATE ON THE SURVIVAL RATE 
OF MICE INOCULATED WITH A LETHAL INTRAPERITONEAL
INOCULUM OF C. albicans.............................  70
THE EFFECT OF INTRAPERITONEAL PRE-INOCULATION
WITH ERYTHROMYCIN LACTOBIONATE ON MITOGEN INDUCED
MOUSE SPLEEN LYMPHOCYTE TRANSFORMATION...............  70
THE EFFECT OF INTRAVENOUS PRE-INOCULATION WITH 
ERYTHROMYCIN LACTOBIONATE ON MITOGEN INDUCED MOUSE 
SPLEEN LYMPHOCYTE TRANSFORMATION....................  75
EVALUATION OF THE AIR BLEB METHOD TO DETERMINE THE
IN-VIVO C. albicans INDUCED MIGRATION RATE OF
PMNLs...............................................  75
THE EFFECT ON THE RATE OF % PHAGOCYTIC UPTAKE BY 
PMNLs OF C. albicans PREVIOUSLY EXPOSED TO 
ERYTHROMYCIN........................................  78
THE EFFECT OF ERYTHROMYCIN BASE ON INTRA-CELLULAR 
KILLING OF YEASTS BY HUMAN POLYMORPHONUCLEAR 
LEUCOCYTES IN-VITRO. ...............................  78
XIV
THE EFFECT OF THE ADMINISTRATION OF ERYTHROMYCIN
STEARATE ON MITOGEN INDUCED TRANSFORMATION OF HUMAN 
LYMPHOCYTES CONTAINED IN WHOLE BLOOD................  80
THE EFFECT OF THERAPEUTIC CONCENTRATIONS OF 
ERYTHROMYCIN ON THE MIGRATION OF HUMAN PMNL 
IN-VITRO............................................  80
THE OBJECTIVE FILTER BASED, ENZYMATIC METHOD FOR 
THE IN-VIVO MEASUREMENT OF THE MIGRATION OF HUMAN 
POLYMORPHONUCLEAR LEUCOCYTES........................  84
THE EFFECT OF AN ORAL ADMINISTRATION OF ERYTHROMYCIN ON 
THE IN-VIVO MIGRATION OF HUMAN PMNLs................ 92
CHAPTER IV. DISCUSSION............. 94
REFERENCES...........................  102
XV
SUMMARY.
The Literature Review covers the immunosuppressive and 
immunopotentiating properties of antibiotics on the 
immune system and the effects these could have on the 
resolution of an infection. The possible pathogenic 
mechanisms of C. albicans are also reviewed in this 
section.
The experimental section shows that pre-treatment of 
mice with erythromycin increases the mean survival time 
following intraperitoneal inoculation of C. albicans.
It was shown that erythromycin enhanced lymphocyte 
transformation and PMNL migration in both in-vivo and 
in-vitro situations. These enhanced immunological 
components probably caused improved survival times in 
the aforementioned animal experiments.
To investigate the effects of oral administration of 
erythromycin on in-vivo PMNL migration in adult 
volunteers a new quantitative test which could only be 
applied to humans was developed and is described in 
detail. Using this method preliminary data were 
obtained which show that erythromycin increases PMNL 
migration in-vivo.
Erythromycin in addition to well documented 
antimicrobial activity also possess immunostimulatory 
properties which, although of secondary consideration, 
may contribute to the eradication of microbial 
pathogens during chemotherapy with this antibiotic.
XVI
LITERATURE REVIEW.
CHAPTER I
LITERATURE REVIEW
The successful antibiotic-mediated resolution of a 
bacterial infection is not merely dependent upon the 
effect of the antibiotic on the causative organism(s) 
but rather is the result of an interplay of host, 
antibiotic and pathogenic factors. Some relevant 
considerations which determine the outcome of 
antibiotic therapy are:-
1 The direct antibiotic effects on the infecting 
bacteria.
2 Indirect antibiotic effects on the infecting 
bacter ia.
3 The achievement of adequate serum antibiotic 
levels.
4 The failure of the immune system to neutralize 
intracellular pathogens.
5 The ability of the antibiotic to cross biological 
membranes.
6 Antibiotic-immune system interaction.
6.1 Antibiotic effects on chemotaxis.
6.2 Antibiotic effects on phagocytosis.
6.3 Antibiotic effects on lymphocyte
transformation.
6.4 Antagonistic antibiotic effects on 
antibodies.
6.5 Enhancing antibiotic effects on 
antibodies.
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6.6 Antagonistic antibiotic effects on 
complement.
6.7 Antibiotic effectiveness associated wi 
a general suppressed immune system.
THE DIRECT ANTIBIOTIC EFFECTS OF ERYTHROMYCIN ON THE 
MICROBIAL PATHOGEN.
Erythromycin:- Erythromycin belongs to a group of 
antibiotics called macrolides and is a metabolic 
product of Streptomyces erythreus which was isolated 
from a soil sample originating in the Phillipines in 
1952 (Smith 1977). There are four erythromycins and 
their structures are shown in FIGURE 1 (Garrod and 
O'Grady 1971).
Rl R2
Erythromycin A OH Me
Erythromycin B H Me
Erythromycin C OH H
Erythromycin D H H
FIGURE 1: Structures of the 4 erythromycins.
Mode of action:- The two suggested mechanisms of 
action of erythromycin are, a) that it is an inhibitor 
of peptide bond formation (Mao and Robinshaw 1972 and 
Mao and Robinshaw 1971) and b) that erythromycin 
inhibits translocation (Tanaka et al. 1973, Igarashi et 
al. 1969 and Cundliffe and McQuillen 1967).
Otaka and Kaji (1982), postulated that erythromycin, 
binds to the 50S ribosome sub-units in growing bacteria, 
this is supported by Wilhelm and Corcaran (1967), and 
Fernandez-Munoz et al. (1971).
Once the nascent oligopeptides reach a certain size, 
erythromycin can not stop further elongation of the 
chain and protein synthesis goes on until that ribosome 
completes translation of one cistron. In a sense, 
erythromycin acts as if it is an initiation inhibitor 
because it only binds to ribosomes with either no 
peptidal tRNA or short peptidal tRNA. This is 
consistent with the evidence put forward by Tai et al. 
(1974).
Administered orally or parenterally erythromycin 
diffuses well into body fluids and tissue with the 
exception of brain. It also enters into pleural and 
peritoneal cavities (Smith 1977).
The intravenous dosage for man is 500 mgm. of 
erythromycin lactobionate administered 6 hourly, which 
develops immediate blood levels of 11,5 to 30,0 
microgram/ml.
Erythromycin has a half life of 1-2 hours (Garrod and 
O'Grady 1971). Erythromycin is excreted both in urine
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and in bile, but only a fraction of the dose can be 
accounted for in this way (Garrod and O'Grady 1971). 
With so little recoverable from the urine and bile, the 
greater part of the drug must be broken down in the 
body (Garrod and O'Grady 1971). Mao and Tardrew 
(1965), have shown that an enzyme capable of 
demethylating erythromycin is widely distributed in 
rabbit tissue, the greatest activity being found in the 
liver.
The action of erythromycin is predominantly 
bacteriostatic in low concentrations. Somewhat higher 
concentrations are distinctly bactericidal (Garrod and 
O'Grady 1971). Balbirsingh et al. (1978) reported that 
when using erythromycin stearate dosages within the 
usual recommended range, there was lethal in-vivo 
action. The lethal in-vivo action could be observed by 
means of scanning and transmission electron microscopy, 
of secretions or tissue samples or both from patients. 
This does not however exclude a contribution by the 
immune system.
Toxicity:- Untoward effects resulting from the use of 
erythromycin are rare. However, occasionally 
hypersensitivity and jaundice can occur after the 
patient has taken the drug for 10 days (Smith 1977).
The above clnically observable toxic effects are taken 
as non-applicable to this dissertation as the
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erythromycin regimen applied to the mouse experimental 
model (to be described) consisted of only one dose of 
erythromycin within therapeutic levels. Further the 
experiments were concluded well within 7 days.
INDIRECT ANTIBIOTIC EFFECTS ON THE INFECTIVE MICRO­
ORGANISMS DUE TO ANTIBIOTIC MEDIATED CHANGES.
Antibiotic mediated changes of bacteria:- Some 
antimicrobial agents indirectly enhance the host 
phagocytic response. A number of studies have shown 
that even at subminimal inhibitory concentrations, 
certain antimicrobial agents indirectly decide the fate 
of micro-organisms by rendering them more susceptible 
to host immune-defence systems (Lorian 1980). 
Enhancement of phagocytosis by this mechanism usually 
occurs as a consequence of antibiotic mediated changes 
in the cell wall or capsular integrity of the target 
bacteria, the consequence being disruption of 
anti-phagocytic surface components and increased 
complement fixation, opsonisation and phagocytosis. 
Antibiotic-induced increased phagocytosis of bacteria 
by this mechanism at sub-minimum inhibitory 
concentrations has been reported for
carbenicillin-treated Pseudomonas aeruginosa (Nishidi 
et al. 1976), naficillin-treated Staphylococcus aureus 
(Friedman and Warren 1974), Streptococcus pyogenes 
exposed to clindamycin (Gemmell et al. 1981 and
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Gemmell et al. 1982), lincomycin (Gemmell and 
Abdul-Amir 1980), erythromycin and penicillin (Gemmell 
et al. 1982) .
BACTERIAL INHIBITION OF THE HOST'S IMMUNOLOGICAL 
DEFENCE MECHANISMS.
Once the bacteria have breached the host's mechanical 
defence mechanisms (skin, epithelium etc.), an 
infection can ensue. This is dependent on the ability 
of the bacteria to protect themselves against the 
host's cellular/humoral immunological defence 
mechanisms. The bacterial anti-host defence mechanisms 
include anti-phagocytic capsules as well as toxins such 
as leucocidin etc. Of particular interest is the 
ability of certain bacteria to invade cells, and 
thereby gain protection from the host's specific 
immunologic defence mechanisms. Legionella 
pneumophila, that once phagocytosed, can resist being 
killed by the phagocyte's killing mechanisms, and can 
even multiply within the human phagocyte. Thus 
phagocytes can serve as a haven where intracellular 
parasites such as Legionella can thrive and multiply, 
protected from the body's normal antimicrobial 
mechanisms, (Miller et al. 1984). The privileged 
position occupied by these intracellular 
micro-organisms can produce prolonged or recurrent 
infections, (World Health Organisation 1973).
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The optimal therapy for infections due to facultative 
intracellular micro-organisms requires the use of 
antibiotics that can penetrate cells, including 
phagocytes, and which are bioactive intracellularly 
(Prokesch and Hand 1982).
THE ACHIEVEMENT OF ADEQUATE SERUM ANTIBIOTIC LEVELS.
Effective in-vivo antibiotic action, can only be 
achieved if an adequate concentration of active 
antibiotic reaches a sensitive micro-organism. Factors 
governing this are, absorbtion, protein-binding, 
metabolism of antibiotic by the host, excretion by 
kidneys, action on antibiotic by bacterial enzymes 
(e.g. betalactamase) and the transport of antibiotic to 
the infected sites by blood supply and or cells such as 
polymorphonuclear leucocytes (PMNLs).
THE FAILURE OF THE IMMUNE SYSTEM TO NEUTRALIZE
INTRACELLULAR PATHOGENS.
An intracellular micro-organism is one that has the 
ability to establish a privileged position within a 
cell. The class of cell that offers the greatest 
interest is the phagocyte.
The functions of phagocytes are to migrate to the site 
of the invasive antigen, phagocytose, and mediate 
the intracellular destruction of the antigen. The
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repertoire of killing mechanisms available to the 
phagocyte consists of agents amongst the most reactive 
known to chemistry, viz. the superoxide anion, hydrogen 
peroxide, the hydroxyl radical and possibly singlet 
oxygen (Babior 1978). Oxygen independent killing 
mechanisms which also participate include lysosomal 
hydrolysis, lysozyme and rapid acidification of 
phagocytic vacuoles. There are pathogens which 
parasitize macrophages and replicate intracellularly 
by avoiding the above destructive processes. Such 
organisms include Listeria, Salmonella, Brucella, 
Mycobacteria, Chlamydia and J^ick^ts^a species. 
Bacterial intraphagocytic survival can be explained 
by mechanisms that avoid triggering of the 
above killing mechanisms. In the case of 
M. tuberculosis the defensive mechanisms of the 
bacteria consist of the production of catalase 
and sulpholipids that interfere with the fusion of 
lysosomes and phagosomes. Leishmania and 
M. lepraemurium survive within phagosomes despite 
fusion with lysosomes. The latter bacterium is 
ensconced in a peptoglycolipid that resists lysosomal 
hydrolysis (Nathan et al. 1980). Legionella 
pneumophila also resists killing by both cellular and 
humoral factors (Horowitz et al. 1981a and Horowitz et 
al. 1981b). When antibiotic therapy is being considered 
for the treatment of the above bacteria, of prime 
importance is whether the selected antibiotic can 
traverse the cell membrane of the host cells.
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THE ABILITY OF ANTIBIOTICS TO CROSS BIOLOGICAL
MEMBRANES.
Legionella spp., which are facultative intracellular 
bacteria, and Chlamydia spp., which are obligate 
intracellular parasites, are organisms known to 
parasitize a large number of cell types (Martin et al. 
1985) .
The intracellular location of these micro-organisms 
protect them from antibiotics that are unable to 
cross biological membranes and exert their action 
(Martin et al. 1985). This is supported by Prokesch 
and Hand (1982), who have shown that these 
micro-organisms survive intracellularly even when 
incubated with certain antibiotics at a level well 
above the lethal concentration for that particular 
organism. The possible explanation for this phenomenon 
is that these antibiotics penetrate phagocytes poorly. 
Penicillin G and cephalosporin antibiotics fail to 
penetrate either alveolar macrophages (AMs) or PMNLs 
efficiently. This probably reflects the limited lipid 
solubility of these drugs and the inability of these 
drugs to cross the biological membranes. Previous 
studies have suggested that antibiotics with good lipid 
solubility penetrate biological membranes, and thus are 
accumulated by mammalian cells (Kornguth and Kunin 
1976, Mandell 1973 and McLeod et al. 1977). These 
observations are supported by the observation that
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chloramphenicol, rifampin and lincomycin, drugs which 
are lipid soluble, achieve intracellular concentrations 
in both PMNLs and AMs twice that of the extracellular 
medium (Prokesch and Hand 1982). These findings are 
consistent with the knowledge that one of these drugs, 
rifampin, is able to kill intraphagocytic bacteria 
(Ezer and Soothill 1974). Uptake of rifampin and 
chloramphenicol was independent of cell viability, 
suggesting that entry of these drugs into cells is 
energy independent (Prokesch and Hand 1982). 
Trans-membrane passage of antibiotics is essential for 
effective eradication of intracellular organisms. If 
this trans-membrane crossing is not achieved, the 
protected intracellular organisms will be the cause of 
persistent or relapsed infections.
Erythromycin, belonging to the lipid soluble group of 
antibiotics, has the ability to cross biological 
membranes and undergo concentration within the 
eukaryotic cells. This can occur even after cessation 
of antibiotic therapy (Prokesch and Hand 1982). 
Distribution studies on tissue samples excised from 
dogs and rats have shown that erythromycin is 
concentrated well above blood levels in organs such as 
the liver, spleen, kidney, lung, pancreas and in 
submaxillary and adrenal glands (Lee et al. 1953 and 
Lee et al. 1956). Recent studies (Hand et al. 1983 
and Johnson et al. 1980) have shown that both human 
PMNLs and AMs accumulate erythromycin at intracellular
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concentrations 15 to 24 tiroes of that found in the 
extracellular compartment. For this intracellular 
concentration of erythromycin to take place, viable 
cells, a physiological environmental temperature and 
metabolic energy are required (Prokesch and Hand 
1982) .
Erythromycin is not simply adsorbed on to the surface 
of PMNLs, but is randomly dispersed throughout the 
cytoplasm of cells. The drug does not appear tightly 
bound to any specific cell organelles since it rapidly 
diffuses out of cells upon lowering of the 
extracellular drug concentration (Miller et al. 1984). 
Martin et al. (1985) suggest that this accumulation may 
be responsible for the aberrant levels in plasma 
usually observed after erythromycin administration, and 
that when this intracellular erythromycin is released 
it is in a form still effective against bacteria.
Martin et al. (1985) propose that the intracellular 
localisation of erythromycin may be more relevant when 
treating micro-organisms known to be capable of causing 
an intracellular infection.
The effectiveness of erythromycin in the treatment of 
Legionella infections can be related to, Legionella spp. 
being sensitive to erythromycin, erythromycin being 
able to traverse the biological membranes, and the 
concentration of erythromycin within phagocytes (Miller 
et al. 1984 ) .
Miller et al. (1984) comment that because blood
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contains many PMNLs, each of which can concentrate 
erythromycin and release the drug in an unaltered 
active form, and because PMNLs are drawn to the sites 
of infection by chemotactic factors, it is possible 
that the PMNLs provide a unique drug delivery system 
that transports erythromycin to the various infected 
tissues. In this way erythromycin, through the use of 
a cellular delivery system, may achieve higher levels 
in infected tissues than would otherwise be expected 
from simple blood levels.
ANTIBIOTIC/IMMUNE SYSTEM INTERACTION.
The different mechanisms by which an antibiotic exerts 
a direct bactericidal or bacteriostatic effect on 
bacteria will not be discussed. What is pertinent to 
this dissertation is that in the in-vivo situation 
the cure of an infection is not achieved solely by the 
action of the antibiotic on the bacteria, "in 
isolation". The action of an antibiotic on a 
micro-organism "in isolation", is a necessary feature of 
the in-vitro sensitivity test method for the 
determination of the bacteria's antibiogram. The cure 
of an infection by an antibiotic is due to the action 
of an effective level of antibiotic on a sensitive 
micro-organism in an in-vivo micro-environment. This 
in-vivo micro-environment is influenced by many dynamic 
immunological and non-immunological systems. It might
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be that differences in the in-vitro/in-vivo
micro-environments are occasionally responsible for 
patients not responding to antibiotic therapy as 
indicated by antibiograms.
Since antibiotics were not developed by micro-organisms 
specifically as a medication for the treatment of 
bacterial infections in man, it is not surprising that 
coincident with the desired antibacterial effects 
achieved there can be unpleasant side effects. In 
fact the ratio of antibiotics discovered, that are 
systemically non-toxic or tolerably toxic : to 
non-usable antibiotics because of their prohibitive 
toxicity, is extremely small.
One could define a useful antibiotic as a substance 
produced by micro-organisms that has a systemic 
anti-microbial action in the complex environment of 
the body without being prohibitively toxic to the 
host.
Side effects can be categorised into those that are 
clinically obvious (blindness, loss of balance etc.), 
and those that are not clinically obvious. With the 
development of improved immunological techniques, many 
antimicrobial agents at attainable in-vivo 
concentrations have recently been found to be 
immunosuppressive (Finch 1980, and Miller and North 
1981). Neftel et al. (1983) observed that penicillin-G 
rapidly degrades in an aqueous solution and that the
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resulting products exert a direct toxic effect on the 
myeloid series in the bone marrow. Further,this report 
describes that the addition of fresh or degraded 
penicillin-G to bone marrow cultures is associated with 
inhibition of in-vitro granulopoiesis. The inhibitory 
effect of penicillin-G on in-vitro granulopoiesis is 
seen only when the drug is present during the 
proliferative phase. These covert actions on the part 
of the above antimicrobial agents have remained 
unnoticed due to the lack of obvious clinical symptoms. 
The suppression of the immune system by antibiotics may 
seem of questionable value since short courses of 
treatment with antimicrobial agents are invariably 
successful. According to Miller and North (1981) the 
principal beneficiaries of advances in antimicrobial 
chemotherapy have been healthy (i.e. immunocompetent) 
people with acute infections. Occasionally the results 
of antibiotic therapy, as indicated by in-vitro 
antibiograms, are disappointing, which might be ascribed 
to antagonism between the antimicrobial agent and the 
immune system. Conversely it has been shown that under 
certain in-vitro conditions some antibiotics can have 
an enhancing effect on the immunological system and 
consequently might have an in-vivo advantage over the 
immuno-suppressive antibiotics.
The absence of immunosuppressive properties may be an 
important factor in the selection of antimicrobial
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agents for prophylactic use or in treatment of 
infections requiring long term chemotherapy.
Antibiotic effects on chemotaxis:- Chemotaxis is of 
primary importance in both the specific and 
non-specific immune responses, since a protective 
response is dependent on rapid and adequate 
accumulation of leucocytes at the site of infection. 
This phenomenon is initiated and sustained by a variety 
of humoral factors termed leuco-attractants. The most 
biologically active of these are the complement-derived 
fragment C5a and the low molecular weight lipids 
leukotriene B4 and 5-hydroxyeicosatetraenoic acid, both 
of which are products of 5'-lipoxygenase mediated 
oxidation of arachidonic acid (Ford-Hutchinson et al. 
1980 and Goetzl et al. 1980). Tetracycline (Forsgren 
and Schmeling 1977), doxycycline and lymecycline 
(Forsgren and Schmeling 1977 and Belsheim et al.
1979), have been reported to inhibit PMNL migration at 
therapeutic concentrations in-vitro. It is likely that 
these observations have clinical significance since 
they have been confirmed in two independent in-vivo 
studies. Using a skin chamber technique, one group of 
investigators described inhibition of PMNL chemotaxis 
in-vivo, in each of eight healthy volunteer subjects, 
within 48 hours after initiating a course of doxycycline 
(200 mg. once orally, then 100 mg. orally per day)
15
(Forsgren et al. 1980). Likewise Martin et al. (1974), 
found that systemic administration of tetracycline was 
associated with reduced PMNL chemotaxis. Fusidic acid, 
tobramycin and chloramphenicol have also been reported 
to inhibit human PMNL migration at therapeutic 
concentrations in-vitro (Forsgren and Schmeling 1977). 
In-vitro tests have shown that therapeutic 
concentrations of gentamicin and amikacin inhibit the 
migration of PMNLs (Goodhart 1977 and Seklecki et al. 
1978). These findings have been confirmed by in-vivo 
studies in which gentamicin and amikacin were 
administered in therapeutic doses to normal healthy 
adults (Kahn et al. 1979). The authors state that 
their findings may be clinically significant, 
especially with patients whose immune system might be 
already impaired and require aminoglycoside therapy. 
Commonly used antmicrobial agents which apparently do 
not influence PMNL migration are ampicillin, 
benzylpenicillin, carboxypenicillin, cephalothin, and 
clindamycin (Forsgren and Schmeling 1977).
Erythromycin (van Rensburg et al. 1982 and Anderson et 
al. 1982) and dapsone (Anderson et al. 1981) have been 
found to increase the migration of human PMNLs 
in-vitro at greater than therapeutic concentrations. 
This enhanced PMNL migration to serum derived 
leucoattractants was related to the anti-oxidant 
properties of the antimicrobial agents (Anderson et al.
16
1982 and Anderson et al. 1981). These observations 
were made from in-vitro studies and may not be entirely 
valid in the in-vivo context.
Antibiotic effects on phagocytosis:- Certain
antimicrobial agents have been found to inhibit
phagocytosis and antimicrobial activity. Lehrer (1971)
and Miller and North (1981) reported that sulphonamides
decreased the ability of human PMNLs to kill
C. albicans and C. tropjcalis in-vitro. Anderson et
al. (1980) found that this effect was not due to the
inhibition of phagocytosis of these micro-organisms,
but that sulphadiazine, sulphamethoxazole and
trimethoprim individually and in combination inhibited
activity of the PMNL peroxidase: H 0 :halide system
2 2in-vitro. Other antimicrobial agents which have been 
reported to inhibit PMNL oxygen-dependent antimicrobial 
activity are tetracycline, cephalothin (Welch et al. 
1981), cefotaxime (van Rensburg, et al., 1983) and 
amphotericin B (Bjorksten et al. 1976).
Forsgren et al. (1974) found that doxycycline and 
tetracycline at therapeutic levels inhibit the 
phagocytosis of yeast by human PMNLs. They also 
observed that PMNLs from healthy adult volunteers who 
had ingested one gram of tetracycline 2-4 hours earlier 
had decreased phagocytic capacity for yeast. The 
inhibitory mechanism was not investigated.
There are some antimicrobial agents which enhance host
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responses to infection by increasing phagocyte and
lymphocyte functions. Erythromycin, penicillin, 
cephalothin, chloramphenicol and tetracycline at 
therapeutic concentrations have been reported to 
enhance the phagocytosis of non-microbial particles 
by human PMNLs in-vitro (Mandell and Ehsen 1981).
Since inert non-bacterial particles were used, the 
stimulatory effect observed is likely to be related to 
a direct interaction of the antimicrobial agent with 
the PMNLs.
Antibiotic effects on lymphocyte transformation:- 
Banck and Forsgren (1979) tested the effects of 20 
different antimicrobial agents on lymphocyte 
transformation in-vitro and observed significant 
impairment of the mitogenic responses of both B and 
T-lymphocytes with therapeutic concentrations of 
fusidic acid, nitrofurantoin and doxycycline.
Rifampicin has been found to inhibit antigen and 
mitogen-activated lymphocyte transformation 
in-vitro (Banck and Forsgren 1979, Ruben et al. 1974, 
Grassi and Pozzi 1972 and Goldstein et al. 1976).
In studies using human subjects ingestion of rifampicin 
was associated with depressed lymphocyte transformation 
which was only evident 3-4 months after the 
commencement of antimicrobial chemotherapy (Ruben et
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al. 1974 and Goldstein et al. 1976). The 
antibacterial agents erythromycin (Anderson et al. 
1982), dapsone and cefotaxime (Anderson et al. 1981), 
influence lymphocyte transformation. Ingestion or 
injection of therapeutic doses of these agents is 
associated with increased mitogen-induced lymphocyte 
transformation (Anderson et al. 1981 and Anderson et 
al. 1982).
Antagonistic antibiotic effects on antibodies:- 
Chloramphenicol has been reported to inhibit the 
antibody response in humans. Daniel et al (1965) found 
that production of specific antibodies in response to 
tetanus toxoid was reduced in patients receiving 2-4 
grams of chloramphenicol daily.
Enhancing antibiotic effects on antibodies:- Howie 
(1975) observed an increase in serum igM antibodies in 
11 of 23 patients with acute otitis media treated with 
eryhthromycin and sulfonamides which compared with only 
4 out of 22 patients treated with ampicillin.
These observations suggest the existence of a more 
effective production of antibodies during erythromycin 
treatment than during penicillin treatment. It was 
suggested that this difference may be an example of a 
more effective antigenic stimulation during therapy 
with bacteriostatic antibiotics. It is noteworthy 
however that erythromycin has been reported to possess
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both bactericidal (Balbirsingh et al. 1978) and 
immunostimulatory properties (van Rensburg et al. 1982, 
and Anderson et al. 1982).
Cefotaxime treatment of mice experimentally infected 
with E. cloacae or C. albicans (for which cefotaxime has 
no antimicrobial activity at the concentrations used) 
is associated with increased survival of the mice in 
comparison to controls (Gillisen 1982). These results 
were paralleled with a stimulation of antibody 
production.
Amphotericin B potentiates the antibody response of 
mice to antigens (Blanke et al. 1977) , an effect which 
may be related to potentiation of macrophage activity 
or inhibition of T-suppressor lymphocytes (Little et 
al. 1980).
Antagonistic antibiotic effects on complement:- It has 
been shown that ingestion of ampicillin by normal adult 
volunteers is associated with reduced complement 
activation (Chakrabarty 1981).
Antibiotic effectiveness associated with a general
suppression of the immune system:- Clinical studies in 
humans with neutropenia, agammaglobulinemia 
(Miller and North 1981) and acquired defects 
of cell mediated immunity (CMI) associated with 
different types of cancer (Middleman et al. 1972,
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Johnston and Colley 1969, Nieman and Lorber 1980,
Nirmal et al. 1971 and Schroter and Weil 1977) have 
shown that the responses to antimicrobial therapy are 
frequently poor despite the acquisition of antimicrobial 
concentrations of the antibiotic. These findings 
clearly demonstrate that the optimal activity of 
antimicrobial agents in-vivo is dependent upon an intact 
host immune system. This conclusion has been confirmed 
by results obtained in experimental animals.
Watson et al. (1978) showed that the efficacy of 
ampicillin against infections with L. monocytogenes is 
dependent upon intact host defence mechanisms 
Using a model of optimal but delayed aminoglycoside 
antibiotic therapy in immunologically normal mice 
similar observations were made by Greisman et al.
(1979). In these studies, infection was induced in 
outbred Swiss mice by one of three Gram-negative 
bacterial species (Esch. coli, Pr. mirabilis or 
Kl. pneumoniae) and the antibiotics used were the 
aminoglycosides gentamicin and kanamycin to which these 
micro-organisms were found to be sensitive in-vitro.
An inoculum of Gram-negative bacteria was selected in 
each case that resulted in 90-100% lethality without 
antibiotic therapy and in no mortality with prompt 
antibiotic administration. With each species a delayed 
period was selected before starting antibiotic therapy 
such that despite optimal dosage schedules of
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antibiotics a 50-70% mortality ensued. Using such a 
model of optimal but delayed aminoglycoside antibiotic
therapy the synergistic interactions between the 
antimicrobial agents and specific antisera were 
assessed. Specific antisera when co-administered with 
optimal aminoglycoside antibiotics after the standard 
delay period prevented mortality not preventable by the 
antibiotics alone. In an extension of these 
experiments it was observed that pre-treatment of the 
mice with the immunosuppressive agent cyclophosphamide 
abrogated the protective effects of specific antiserum 
and antibiotic. Although these studies were undertaken 
primarily to study protective mechanisms against 
Gram-negative endotoxemia, they further emphasize the 
beneficial interactions which should occur between the 
host immune system and antimicrobial agents.
According to Miller and North (1981) the principal 
beneficiaries of advances in antimicrobial chemotherapy 
are normal individuals. Immunocompromised individuals 
often have unsatisfactory responses.
PATHOGENICITY OF C.albicans.
C. albicans is considered an opportunistic pathogen 
affecting persons whose host defences are in some way 
or other suppressed (Odds 1979). These 
immunosuppressed groups being, congenital or acquired 
immunological deficiencies, the infant group whose
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immunological defence mechanisms have not fully matured 
and the old, whose immunological defence mechanisms are 
failing. It is still poorly understood which 
mechanisms in fact are responsible for the pathological 
process.
Views presently falling out of favour, are that 
C. albicans is capable of producing an endotoxin and the 
ability of C. albicans to produce pseudomycelia with 
the ability to physically disrupt the phagocytic cell 
(Louria and Brayton 1964, Stanley and Hurley 1969, and 
Odds 1979). Also, two C. albicans cell surface enzymes 
have been described which are similar to substances 
responsible for the pathogenicity of many bacteria.
These are acid phosphatemonoesterase (Odds & Hierholzer 
1973) and phopholipase (Pugh and Cawsen 1975 and Price 
and Cawsen 1977).
An enzyme first described by Staib (1965) as an 
inducible secreted proteinase has recently attracted 
increasing attention as a possible virulence factor.
It has been shown by Macdonald and Odds (1983) that 
there is a correlation between the ability of 
C. albicans to produce this inducible proteinase and 
virulence. For comparison a non-pathogenic proteinase 
deficient mutant prepared from the former virulent 
strain was shown to be incapable of producing the 
inducible proteinase to the extent of the parent 
pathogenic strain. Factors supporting this latter 
hypothesis are that patients suffering from systemic
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Candidiasis frequently have antibodies to this enzyme
(Macdonald & Odds 1980). Further investigations by
Macdonald and Odds (1980) showed that the mortality rate
of mice which had been intravenously inoculated with 
6
1x10 viable cells of the proteinase producing 
C. albicans was 100% in 7 days, whereas the 
mortality of mice inoculated with the same number of 
non-proteinase producing strain was 50% at 34 
days. The way in which the proteinase exerts 
its pathological effects in vivo remain unknown.
Most probably the enzyme mediates tissue 
degradation, assisting the fungus to invade tissue.
An alternative is that the enzyme might be involved 
in defending the fungus against host defence 
mechanisms. This concept is supported by experiments 
showing that phagocytosis and killing of C. albicans by 
PMNLs was markedly reduced in the case of proteinase 
producing C. albicans. The addition of proteinase to 
the non-proteinase producing strains did not influence 
phagocytosis nor the killing ability of the PMNLs, 
indicating that this proteinase is an effective defence 
against phagocytosis and intracellular killing, only 
when it is being actively produced by C. albicans 
(Macdonald & Odds 1983).
It seems that C. albicans rarely causes infections in 
persons with intact immune defences and possesses no 
single virulence factor as potent or as easily 
demonstrable in vivo as, for example, bacterial toxins 
(Macdonald & Odds 1983).
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RATIONALE FOR THIS STUDY.
Successful antimicrobial chemotherapy depends ultimately 
on beneficial co-operative interactions which occur 
between antibiotics and host immune defence mechanisms 
(Miller and North 1981). Antibiotic sensitivity tests 
performed in vitro are therefore not necessarily 
predictive of the full potential of some antimicrobial 
agents since they exclude the enormous contribution 
made by antibiotic/host immune defence interactions in 
the eventual eradication of microbial pathogens. The 
ability to co-operate with host immune defence 
mechanisms is probably a common but variable property 
of antibiotics. Some antibiotics are better equipped 
than others to improve the anti-bacterial defences of 
the infected host. Erythromycin has emerged as an 
antimicrobial agent which interacts beneficially with 
host immune defence mechanisms (Prokesh and Hand 1982). 
In this dissertation interactions which occur between 
erythromycin and certain host immune defence mechanisms 
have been investigated.
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REAGENTS and METHODS.
CHAPTER II
REAGENTS
Ammonium chloride solution.
0,83% ammonium chloride (NH4C1), was dissolved in 
triple glass distilled water, containing 0,1% sodium 
bicarbonate (NaHC03) and 0,074% EDTA.
Ficoll hypaque solution.
1) Sodium metrizoate solution 75% w/v (Nyeggard and 
Co., As. Oslo). One ampoule contains 20 ml.
2) Ficoll powder, molecular wt. of 400000.
Method.
1) Ficoll powder 270 gm.
2) Double distilled water 3000 ml.
3) Heat and stir at 50 deg C.
4) Cool to room temperature.
5) Sodium metrizoate solution 480 ml.
6) Adjust the specific gravity (SG) to 1,1 for 
mouse spleen cells and 0,7 for human blood.
3% Gelatin phosphate buffered saline (PBS).
3,0% gelatin in PBS (0,15 M, pH 7,2) dissolved in a 
56 deg. C. water bath and then cooled to 37 deg. C.
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Gey's fluid.
1) PBS 200 ml.
2) Calcium chloride (CaC12.2H20)
3) Magnesium chloride (MgC12.6H20)
4) Glucose 400 mgm
20 mgm
8 mgm
Heparin solution.
0,3% heparin in triple glass distilled water. The 
solution was filter sterilised.
Nutrient broth No.2 (NB2) AGAR.
NB2 agar consisted of 1% agar (Oxoid Agar No.l) in NB2. 
Nutrient broth No.2.
NB2 (Oxoid CM 67) described as being comparable to 
Nutrient Broth but richer in nutrients. Made up as 
prescribed by the manufacturer.
Medium M199.
1) Medium M199 (Green Island Biological Co., Paisley, 
Renfrewshire, Scotland (Gibco)), containing Hanks salt 
and L-Glutamine, without Sodium carbonate.
2) Streptomycin/Penicillin 10000 units/ml.
Method.
1) M199 medium 11 gm.
2) N-2-Hydroxyethylpiperazine-N1-2-
ethanesulphonic acid (Hepes) 4 gm.
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3) Sodium bicarbonate (NaHC03) 700 mgm.
4) De-ionised water 2 L.
5) Adjust pH with 0,1 N Sodium Hydroxide to 7,1.
6) Streptomycin/Penicillin (10000 units) 20 ml.
Sabouraud dextrose agar (SDA) (Merck Chemicals (PTY) 
Ltd., Federal Republic of Germany).
Sabouraud dextrose Agar. Made up as prescribed by the 
manufacturer.
Sabouraud dextrose broth medium (SDB) (Merck).
Sabouraud dextrose broth media. Made up as prescribed 
by the manufacturer.
Concanavalin A (CON-A) solution, 800 Aig./ml.
Concanavalin A (Sigma Chemical Company, St. Louis, USA). 
Method.
1) CON-A 4 mgm.
2) M199 medium 5 ml.
3) Sterilise by filtraton
4) Dispense into test tubes 0,4 ml.
Phytohaemagglutinin (PHA) solution, 800/ug./ml.
Reagent:- Purified Phytohaemagglutinin (Wellcome 
Diagnostics, Temple Hill, Dartford, U.K.) 2 mgm./phial. 
Method:- As for CON-A solution with the exception that 
CON-A is substituted by PHA.
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Decomplemented serum.
Fresh human serum was decomplemented at 56 deg. C. for 
30 min.
Tritiated thymidine.
Thymidine-methy1-3H (New England Nuclear Corporation; 
Boston; Mass.; USA).
Method.
Stock solution:- H/3 thymidine of 1 mi/Ci per ml. 
dispensed in 50/u/L. volumes per tube and stored at -70 
deg. C.
White cell counting fluid.
1) Gentian violet 1% 1 ml.
2) Acetic acid 2 ml.
3) Distilled water 100 ml.
Erythromycin.
For in-vitro studies erythromycin base was used, 
erythromycin stearate (500 mg. tablets) was used for 
human oral studies and erythromycin lactobionate used 
for animal inoculations.
All forms of erythromycin were obtained from Abbott 
Laboratories Ltd., Abbott Park, North Chicago,
Illinois, U.S.A.
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INSTRUMENTATION.
Beta counter.
All beta counts were determined on a Searle Isocap/300 
Liquid Scintillation Counter.
Spectrophotometer.
The spectrophotometer used was the Pye Unicam SP1700 
Ultraviolet Spectrophotometer.
FORMULA.
Formula to determine the centrifugal force in Gs.
RPM
G = 11,2-----  X R
1000
G = gravity.
RPM = revolutions per second.
R = radius in cm. from the centre of the boss to the 
end of the centrifuge tube.
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EXPERIMENTAL ANIMALS.
The experimental animals were NMRI mice, as described 
by Festing (1973). Origin:- Non-inbred by Poiley. To 
US Naval Med. Res. Inst, at F51, known as NMRI. The 
mice were supplied by the H.F. Grove, Animal Research 
Centre, Pretoria. For test purposes, groups of 20 
mice, excepting where otherwise stated, were matched in 
sex, age (2 months) and weight (20 gm.).
TEST ORGANISMS.
Candida albicans (C. albicans) Y240:CBS5736, was 
supplied by Dr. van der Walt, Council for Industrial 
and Scientific Research, Pretoria. Enterobacter 
cloacae (E. cloacae) ATCC 13047, was obtained from 
Merck Chemicals (PTY) Ltd.
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DETERMINATION OF THE MINIMUM INHIBITORY CONCENTRATION
(MIC) AND MINIMUM ClDAL CONCENTRATION (MCC) OF 
E. cloacae AND C. albicans.
The standard laboratory methods for determining the MIC 
and MCC as described by Cruickshank et al. (1975), were 
used. The serial dilutions of erythromycin, ranged 
from 6 mgm./ml. to 0,01 micro gm./ml. in NB2. The 
results obtained are shown in TABLE 1 (page 58).
DETERMINATION OF COLONY FORMING UNITS (CFU) RELATIVE TO
OPTICAL DENSITY (OD) OF E. cloacae AND C. albicans.
E. cloacae and C. albicans were grown in NB2. After 
washing the micro-organisms three times in PBS, the ODs 
of various dilutions of the concentrated micro­
organisms were read on a spectrophotometer at a 
wavelength of 540 nm. (all OD readings of micro­
organism cell suspensions relating to CFU were read at 
the wavelength of 540 nm.). 0,1 ml. aliquot of each of
the micro-organism dilutions were added to a petri 
dish into which was poured 30,0 ml. of NB2 agar.
Colony counts were performed after incubation periods 
of 48 hrs. for E. cloacae and 72 hrs. for C. albicans. 
Graphs relating OD to CFU/ml. are shown in FIGURES 4 
and 5 (pages 59 and 60).
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PREPARATION OF THE E. cloacae INOCULUM.
E. cloacae was grown in NB2 for 24 hrs. The organisms
were then harvested, washed three times in PBS and
resuspended in PBS. The OD540 was determined on a
1/15 dilution of the inoculating suspension in PBS,
using a spectrophotometer. The OD was adjusted to
6
0,15 equivalent to 115 x 10 CFU/ml. Conversion from 
OD to CFU was by means of the graph in Figure 4 
(page 59).
PREPARATION OF THE C. albicans INOCULUM.
C. albicans was grown in Sabouraud's dextrose agar for
48 hrs. The organisms were then harvested, washed
three times in PBS and resuspended in PBS. The OD540
was determined on a 1/15 dilution of the inoculating
suspension in PBS, using a spectrophotometer. The OD
6
was adjusted to 1,5 equivalent to 16 x 10 CFU/ml. 
Conversion from OD to CFU was by means of the graph in 
Figure 5 (page 60) .
INOCULUM CONCENTRATION OF MICRO-ORGANISMS USED.
E. cloacae:- It was established that a 0,5 ml. inoculum 
of E. cloacae suspension at an OD540 of 0,15 after a 
1/15 dilution in PBS, when inoculated intraperitoneally 
into mice, killed 5/5 mice within 24 hours. This 
concentration of bacteria was used throughout this 
dissertation, unless otherwise stated.
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C. albicans:- It was established that a 0,5 ml. 
inoculum of C. albicans at OD540 of 1,5 after a 1/15 
dilution in PBS, inoculated intraperitoneally into 
mice, killed 5/5 mice within 48 hours. This 
concentration of C. albicans was used throughout this 
dissertation, unless otherwise stated.
DETERMINATION OF THE EFFECTS OF ERYTHROMYCIN ON THE
IN-VITRO GROWTH RATE OF C. albicans AND E. cloacae
USING A TURBIDOMETRIC METHOD.
C. albicans:- A 20 ml. volume of NB2 was inoculated 
with a colony of C. albicans and incubated for 18 hrs. 
The organisms were then washed once and resuspended in 
4 ml. of PBS. 300 ml. of NB2 was inoculated with 60 
micro L. of the above suspension of micro-organism.
The 300 ml. of yeast suspension was dispensed into 
3 X 100 ml. volumes. Erythromycin was added to 2 
volumes of inoculated broth, to arrive at 
concentrations of 7,5 and 30,0 micro gm./ml. of 
erythromycin. The third 100 ml. volume, without 
erythromycin acted as a control. Each 100 ml. volume 
of broth was dispensed into 3 X 20 ml. volumes which 
were then incubated at 37 deg. C. At time intervals of 
16, 24 and 42 hours, 5 ml. samples were taken. The 
samples were washed twice and resuspended in two ml. of
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PBS. The OD540 of these undiluted suspensions of 
micro-organisms were determined, Results are presented 
in TABLE 3 page 6 2.
E. cloacae;- This method was similar to the method used 
to determine the effect of erythromycin on the growth of 
C. albicans, with the exception that the cultures were 
sampled at 18 hrs. only. No further samples were taken 
as there was an obvious indicaton that erythromycin had 
an effect on the growth rate of E. cloacae.
Results are presented in TABLE 2, page 61*
ASSESSMENT OF THE SUITABILITY OF E. cloacae.
Initial justification for the use of E. cloacae in this 
investigation was based on the MIC and MCC as 
previously described. However it was observed that 
erythromycin retarded the growth rate of E. cloacae.
This is illustrated in Table 2. From this point on no 
further experiments using E. cloacae were performed.
MEASUREMENT OF ERYTHROMYCIN LACTOBIONATE IN THE PERITONEUM
OF MICE, AT VARIOUS TIME INTERVALS AFTER INTRAPERITONEAL
INOCULATION.
A 0,5 ml. volume of a 3 mgm./ml. solution of erythromycin 
lactobionate was inoculated into the peritoneum of four
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mice. At intervals of 0, 15, 30 and 60 minutes a mouse was 
sacrificed. Immediately after sacrifice, 2 ml. of PBS was 
introduced into the peritoneum and the abdomen massaged for 
two minutes. The peritoneal cavity was then opened and the 
peritoneal wash harvested. The peritoneal fluids were 
assayed for erythromycin lactobionate. Results are 
shown in TABLE 4 (page 64).
DETERMINATION OF THE TOXICITY OF ERYTHROMYCIN
LACTOBIONATE INOCULATED INTRAPERITONEALLY INTO MICE.
3 groups of six mice, were inoculated with 1,0 ml. of 
a 3,0, 2,0 and 1,0 mg./ml. solutions of erythromycin 
lactobionate in PBS, intraperitoneally. The result of 
this experiment is presented on page 63.
INVESTIGATION OF THE EFFECT OF BENZYL ALCOHOL (PRESENT
AS A PRESERVATIVE IN ERYTHROMYCIN LACTOBIONATE) ON THE
SURVIVAL RATE OF MICE INOCULATED WITH C. albicans.
A group of mice were inoculated with 0,5 ml. of a 0.9 
mg./ml. suspension of benzyl alcohol in PBS (the 
effective dose being 0,45 mg. per mouse) this amount 
being contained in 1 mg. of erythromycin lactobionate.
The control group was inoculated with 0,5 ml. of PBS.
One hour after the above inoculation the two groups of 
mice were inoculated with C. albicans intraperitoneally. 
Results are shown in FIGURE 6 (page 66).
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EFFECTS OF ERYTHROMYCIN ADMINISTRATION ON THE SURVIVAL
RATE OF MICE INFECTED WITH A LETHAL INTRAPERITONEAL 
INOCULUM OF C. albicans.
Groups of twenty, two month old , sex-matched NMRI mice 
weighing approximately 20 gm. were used. The animals in 
the experimental group were inoculated as follows.
1) LD 50 experiment (C. albicans OD 1,3); 
intraperitoneal erythromycin inoculation with 1 mg. of 
erythromycin lactobionate in 0,5 ml of PBS. Results 
shown in FIGURE 7 (page 67).
2) LD 100 experiment; intraperitoneal erythromycin 
inoculation with 1 mg. of erythromycin lactobionate in 
0,5 ml of PBS. Results shown in FIGURE 8 (page 68).
3) LD 100 experiment; intraperitoneal erythromycin 
inoculation showing a dose response curve; inoculums 
consisted of 1 mg. and 0,5 mg, of erythromycin 
lactobionate respectively in 0,5 ml. of PBS. Results 
shown in FIGURE 9 (page 69).
4) LD 100 experiment; a series of four experiments; 
inoculations were by the intravenous route with 0,1 mg. 
of erythromycin lactobionate in 0,2 ml. of PBS.
Results are shown in FIGURES 10a, 10b, 10c and 10d 
(page 71).
Control mice were inoculated with an equivalent 
amount of lactobionic acid, in the same volume of 
inoculum as the test, via the same route as the test.
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After a 60 min. delay period the mice were lethally
7
infected intraperitoneally with 2x10 CFU (OD 1,5) 
of C. albicans.
Prior to each series of experiments the C. albicans 
were passaged twice in mice, re-isolated, cultured in- 
vitro , harvested, washed and the OD540 determined and 
adjusted as previously described prior to injection.
The results were recorded as accumulated deaths against 
time after the lethal inoculation with C. albicans. 
Solutions were coded and decoded only on completion of 
the experiment.
Statistical analysis of the results were performed 
using the Student's t-test for two means.
INVESTIGATION OF THE EFFECTS OF PRE-INOCULATION WITH
ERYTHROMYCIN LACTOBIONATE ON MITOGEN INDUCED MOUSE
SPLEEN LYMPHOCYTE TRANSFORMATIONS.
Mice were pre-inoculated with 1 mgm. of erythromycin 
lactobionate in a volume of 0,5 ml PBS 
intraperitoneally or 0,1 mgm. of erythromycin 
lactobionate in 0,2 ml. of PBS intravenously 2 hours 
before sacrifice. Control mice were inoculated as 
above, excepting that lactobionic acid was used instead 
of erythromycin lactobionate.
Spleens were removed aseptically from the sacrificed 
mice and placed into M199 medium.
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Lymphocytes were harvested from the spleens by firstly 
slicing the spleens, suspending the sliced spleens in
about 0,5 ml of M199 and then grinding the sliced
spleens gently in a Thompson Tissue Grinder.
The ground spleen suspensions were made up to a volume
of 5m1 in M199, layered onto 5 ml of ficoll—hypaque
(S.G. 1,1) and centrifuged at 1200 RPM for 30 min.
(242xG). Lymphocytes concentrated at the
Ml99/ficol1-hypaque interface were harvested, washed
twice with M199 and suspended in 1 ml of M199.
A lymphocyte count was then performed and the
6
lymphocyte concentration adjusted to 4X10 lymphocytes 
per ml.
Into round bottomed micro-titre trays 0,1 ml of M199, 
0,02 ml of decomplemented serum and 0,05 ml. of the 
lymphocyte cell suspension was added. To the above,
0,02 ml of either phytohaemagglutinin or concanavalin-A 
in the following concentrations was added, 6, 12,5, 25, 
50, 100, 200, 400 and 800 micrograms/ml. A back ground 
(BG) control consisted of one series of triplicate 
wells containing the above reagents with the exception 
that 0,02 ml of M199 instead of mitogen was added. The 
trays were then incubated for 36 hours, after which the 
cells were pulsed with 0.02 ml of tritiated thymidine 
(0,5^a Ci) and incubated for exactly 18 hours, 
harvested and the radioactivity determined in counts per
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minute (CPM) in a beta counter. Triplicate wells were 
included for each mitogen concentration.
Intraperitoneal results are expressed as the means of 
four series of tests and are shown in TABLES 6 and 7 
(pages 73 and 74).
Intravenous results are shown as above in TABLES 8 and 
9 (pages 76 and 77).
MOUSE AIR BLEB METHOD TO EVALUATE THE IN-VIVO MIGRATION 
RATE OF PMNLs.
Lawman et al. (1984) described the following technique 
which is a modification of the techniques of 
Higginbotham (1968) and Clark et al. (1979).
The procedure consisted of:-
1) A connective tissue air bleb was generated by 
injecting 0.9 ml. of air subdermally on the back of a 
mouse to one side of the midline and away from the neck 
region.
2) 0,1 ml of a C. albicans suspension (OD 1,5) was 
inoculated into the air bleb. C. albicans was used as 
a leucoattractant instead of FMLP. This was justified 
as C. albicans is a recognised leucoattractant and was 
the predominant micro-organism used in this 
dissertation.
3) At two and four hour intervals after the injection
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of the C. albicans suspension, mice were sacrificed and
the skin was surgically removed exposing the thin 
membranous lining of the bleb.
4) The membraneous lining of the bleb was excised and 
gently stretched onto a coverslip.
5) The membranous lining was fixed in ethanol and 
stained with Harris's haematoxylin stain.
6) Evaluation was done microscopically in terms of 
PMNLs per high power field.
Results are dicussed on page 75.
PREPARATON OF HUMAN PMNL SUSPENSION.
PMNLs were isolated from heparinised human venous 
blood. The blood was diluted 1/2 with PBS, 
and layered onto ficoll/hypaque. The layered 
blood-ficoll/hypaque tube was centrifuged at 1200 RPM 
(290xG) for twenty minutes. The supernatant of the 
ficoll/hypaque tube was discarded. The RBC/PMNL 
deposit was resuspended in 20 ml. of a 3% gelatin in 
PBS solution, and incubated at 37 deg. C for 20 min.
The PMNL rich top layer was transferred into a round 
bottomed 25 ml. container and centrifuged at 1800 RPM 
(363xG) for 10 min. The supernatant was discarded, 
the container filled with ammonium chloride solution 
and the cells resuspended. The cell suspension was 
incubated at 4 deg. C for 10 min. to lyse the
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contaminating RBC and then centrifuged at 1800 RPM 
(653xG) for 10 min. This deposit consisted of PMNLs. 
The PMNLs were resuspended in 0,9 ml of Gey's fluid and 
the final PMNL concentration adjusted as required.
This method routinely yielded PMNL suspensions of high 
purity ( > 95% ) and viability ( > 90% ).
THE EFFECT ON THE RATE OF % PHAGOCYTIC UPTAKE BY PMNLs
OF C. albicans PREVIOUSLY EXPOSED TO ERYTHROMYCIN.
C. albicans was inoculated into NB2 containing 20 /u/Ci
of tritiated thymidine (thymidine-methyl-3H, New
England Nuclear Corp., Boston, Mass.) per 10 ml. of
broth. The above culture was divided into 3 X 20 ml.
aliquots, to which was added erythromycin in the
following concentrations, 0,0, 5,0 and 30 micro gm./ml.
The cultures were incubated for 72 hrs. at 37 degrees
C. After incubation the yeasts were washed three times
(2000xG for 15 min.) with sterile glucose PBS and the
yeast suspension then adjusted to a concentration of 8
5x10 CFUs/ml. in glucose PBS, by means of a
haemacytometer. The yeasts were then pre-opsonized by
incubating 0,3 ml. of the yeast suspension with 1,2 ml.
of 5% fresh human serum in PBS for thirty minutes at 37
degrees C on a rotator. The yeasts were washed three
times (2000xG for 15 min.) with PBS and resuspended to
8
a concentration of 1x10 yeasts/ml. in PBS. A PMNL
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described previously and adjusted to a concentration of 7
1x10 PMNLs/ml. in PBS. The phagocytosis assay
5 6consisted of adding 5X10 PMNLs to 5X10 radiolabelled
opsonized yeasts in a volume of 2 ml. PBS. This
PMNL/yeast suspension was incubated on a rotator at 37
7
deg. C. A tube consisting only of 5X10 radiolabelled 
yeasts in 2,0 ml. was processed in parallel with 
PMNL/organism suspension, to determine the counts per 
min. (CPM) of the total yeasts used. Aliquots of 0,5 
ml. PMNL/organism suspensions were transferred into 
2,5 ml. ice cold PBS after 2, 5 and 15 min. 
incubation, centrifuged (500xG. for 5 min.) to deposit 
the PMNLs and washed twice to remove non-phagocytosed 
yeasts. The radioactivity associated with the PMNLs 
and phagocytosed yeasts were measured in a beta counter. 
The results are expressed as the percentage of uptake 
of radiolabelled C. albicans by PMNLs.
CPM in PMNL pellet
% phagocytosis = ------------------------ X 100
CPM in total yeast pellet
The results are presented in TABLE 10 (page 79).
suspension was prepared from normal human volunteers as
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KILLING OF YEASTS BY HUMAN PMNLs IN-VITRO.
In the study of the intracellular bioactivity of
erythromycin, PMNLs from normal individuals were
incubated with opsonized C. albicans in the ratio of
1 PMNL:10 CFUs of C. albicans for 30 min at 37 deg. C in
a final volume of 1 ml. of Gey's fluid containing 
6
5 x 10 PMNLs and erythromycin from 0,3 to 20 ^ ugm./ml. 
The PMNL/yeast/erythromycin mixtures were rotated on a 
turntable for 30 min. at 37 deg. C. The PMNLs and 
phagocytosed yeasts were then pelleted and washed by 
centrifugation at 250 G for 10 min., and the 
extracellular yeasts were removed. The PMNL pellet 
containing the phagocytosed C. albicans was suspended 
in the same erythromycin concentrations after removal 
of extracellular yeasts. The PMNL/intracellular 
yeast/antibiotic mixtures were then incubated for 4 
hrs. at 37 deg. C, after which the PMNLs were washed 
three times in PBS to remove the antibiotic. The 
intracellular yeasts were released by distilled water 
lysis of PMNLs and 50 ytil. of the lysate was inoculated 
into nutrient broth containing radiolabelled amino acids 
and incubated for 8 hrs. at 37 deg. C. The yeasts were 
then washed three times in PBS, and the extent of the
incorporation of radiolabelled amino acids into the 
yeast cells was measured in a liquid scintillation 
counter. These results are
THE EFFECT OF ERYTHROMYCIN BASE ON INTRA-CELLULAR
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expressed as radioactive CPM. PMNLs were omitted in 
identically processed control systems containing yeasts 
and erythromycin only. The result is discussed on 
page 78.
MITOGEN-INDUCED TRANSFORMATION OF HUMAN BLOOD
LYMPHOCYTES, AFTER THE ADMINISTRATION OF A 500 mg. DOSE
OF ERYTHROMYCIN STEARATE, USING A WHOLE-BLOOD METHOD.
To exclude the "washing-off" effect of cell-preparative 
procedures a whole blood method for lymphocyte 
transformation was developed to eliminate the loss of 
leucocyte-associated erythromycin. The method is 
identical to that described for pure mouse spleen 
lymphocytes with the exception that 20 /il. of 
whole blood was added to each well instead of 
purified lymphocyte suspension. The method was 
applied to investigate the effect of oral 
administration of erythromycin stearate on 
leucocyte transformation. Blood specimens were taken 
before and 2 hours after the administration of a single 
500 mg. oral dose of erythromycin stearate to 6 adult 
volunteer subjects (informed consent was obtained and 
administration of the antibiotic was clinically 
supervised). Mitogen-induced transformation was 
performed using 4 concentrations of PHA and CON-A (3, 
25, 50, and 100 /ug./ml.). Results are shown in TABLES 
11 and 12 (pages 81 and 82).
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THE EFFECTS OF THERAPEUTIC CONCENTRATIONS OF
ERYTHROMYCIN ON THE MIGRATION OF HUMAN PMNLs 
IN-VITRO.
PMNLs were purified from human venous' blood as
described previously and resuspended to a
6
concentration of 6X10 PMNLs per ml. of Hanks
balanced salt solution (HBSS) pH 7,4, supplemented
with 0,05% bovine serum albumin (BSA). One ml.
aliquots of PMNL suspension were incubated at 37 deg.
C. for 15 min. followed by the addition of an equal
volume of erythromycin base to give final
concentrations of 1,75, 3,5, 7,0, 17,5 and 35/agm./ml.
6
and a final PMNL concentration of 3X10 /ml. Control 
(antibiotic-free) systems received 1 ml. of HBBS.
PMNLs with and without erythromycin were 
incubated for a further 15 min. at 37 deg. C. PMNL 
migration was then measured using modified Boyden 
chambers (Anderson et al. 1981). The upper cell 
compartment of the chamber was separated from the lower 
leucoattractant chamber by a 5 /am. pore size 
nitrocellulose filter (Sartorius Membranfi1ter, 
Gottingen FRG). Two hundred/al. of control or 
erythromycin-treated PMNL suspension were delivered 
into the upper compartment of each chamber. Into the 
lower compartments of each chamber 1 ml. of HBSS
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containing the leucoattractant endotoxin-activated 
serum (EAS) was added. Erythromycin was also present 
in the lower chambers to maintain a constant antibiotic 
concentration. EAS was generated by incubating 1 ml. 
of fresh autologous serum with 500 ^ gm. of bacterial 
endotoxin for 30 min at 37 deg. C. followed by dilution 
with HBSS. EAS was used at a final optimum 
concentration of 10%. The chambers were incubated for 
45 min. at 37 deg. C., after which the chambers were 
removed and immersed in methanol to fix the PMNLs to 
the filter and to detach the filters. The filters were 
then stained with haematoxylin, dehydrated in ethanol 
and cleared in xylene. The filters were then placed on 
glass microscope slides and the numbers of PMNLs which 
had traversed from top to bottom in response to the 
gradient of EAS were enumerated microscopically and the 
results expressed as PMNLs per microscope high-powered 
field (PMNL/HPF). EAS was excluded from random 
migration (background) systems and these values +- 
erythromycin were subtracted from corresponding EAS 
systems to give the real values for EAS.
The results are shown in TABLE 13 (page 83).
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AN OBJECTIVE, FILTER BASED ENZYMATIC METHOD FOR THE 
IN-VIVO MEASUREMENT OF THE MIGRATION OF HUMAN 
POLYMORPHONUCLEAR LEUCOCYTES.
Adult volunteers:- Informed consent was obtained from 
the volunteers and the study was approved by the Human 
Investigations and Research Committees of the Faculty 
of Medicine of the University of Pretoria. Adult male 
volunteers were used with a mean age of 28 +- 2 years 
(range 22 - 52) .
Blister apparatus:- This is shown in Figure 2.
The device was based on that described by Helium and 
Solberg (1977) and consists of a suction block with 
eight outlet pipes, leading into a manifold with 
individual control valves for each outlet pipe, 
connected by a Y-tube to a suction pump (Model 13156 
pressure/vacuum pump, Gelman Instruments Co, Ann Arbor, 
Michigan, U.S.A). The transparent plexiglass suction 
block (9,5cm. x 4,5cm. x 3cm.) contained 8 cylindrical, 
vertical, polished bores in a parallel, longitudinal 
arrangement of two rows of 4 bores. Each bore 
terminated in a shallow circular groove on the lower 
surface of the suction block. The short airtight 
outlet pipes were inserted into each bore and firmly 
attached to plastic connecting tubes leading into the 
manifold (10cm. x 5cm. x 2,5cm.) which contained 8 
control valves to regulate individual blister 
formation.
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Blister-induction:- The volar surface of the forearm 
was shaved and cleaned with 90% ethanol. The suction 
block was placed on the mid-volar area and fixed in 
position with 3 strips of adhesive tape (FIGURE 2).
All the control valves on the manifold were fully 
opened and a suction pressure of 400 mm. of mercury 
applied and maintained throughout the blistering 
period. The blistering process was monitored visually 
through the transparent suction block. As described by 
Helium and Solberg (1977) blister formation started at 
about 75 minutes, as minute blisters which coalesced to 
form a half spherical bulla as the dermo-epidermal 
separation reached the circumference of the bore, 
within 105 minutes. Closure of the appropriate valves 
slowly released the suction on the formed blisters 
preventing the first formed blisters from bursting 
while waiting for slower-forming blisters to develop. 
When all 8 blisters were formed the suction device was 
detached. A typical completely-formed blister is shown 
in FIGURE 3a. Using sterile forceps applied to the 
base of the blister, the blister fluid, epidermal 
blister roof and the basement membrane were torn-off at 
the blister circumference, leaving circular areas of 
denuded dermis approximately 0,8 cm squared (FIGURE 3b). 
Attempts were made to obtain bulla on animals with 
the following results:- pigs, sheep, dogs and rabbits 
developed haematomas instead of bulla, the baboon was 
the only animal other than human that produced a bulla
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FIGURE 2: Photograph of the suction blister apparatus
applied to the upper forearm of an adult volunteer 
subject. The suction block (A) and manifold (B) with 
control valves can be easily identified.
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when the suction apparatus was placed on the abdomen. 
The baboon model had to be abandoned as it was 
necessary to immobilise the baboon with a general 
anaesthetic. It has been well documented that 
anaesthetics have an inhibiting effect on PMNL 
motility.
Measurement of PMNL accumulation:- To standardise the 
area of denuded dermis adhesive ring reinforcers with a 
central circular hollow zone of diameter 5 mm. were 
placed onto each region of exposed dermis as shown in 
FIGURE 3c. The central exposed areas of dermis were 
moistened with 50 micro litres of Hanks' balanced salt 
solution without phenol red (HBSS, Flow Laboratories 
Ltd., Irvine, Scotland) as shown in FIGURE 3d. A 
single nitrocellulose filter of porosity 0,2 microns or 
a double filter combination with pore sizes of 5 
microns and 0,2 microns respectively were placed onto 
the moistened exposed dermis as shown in FIGURE 3e.
The filters (13 mm. diameter; 150 microns depth) were 
obtained from Sartorius Membranfilter Gottingen, FRG. 
The single 0,2 micron pore size filter was chosen to 
permit PMNL accumulation on the lower surface of the 
filter in contact with the dermis with minimal 
intra-filter penetration of PMNLs. The double filter 
system was used to increase the surface area available 
to PMNLs. Filter-adherent PMNLs could thus migrate 
onto and through the 5 micron pore size filter and be 
collected on the PMNL impregnable 0,2 micron upper 
filter.
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The synthetic chemotactic tripeptide
N-formyl-L-methiony1-L-leucyl-L-phenylalanine (FMLP;
Bio-Yeda Ltd, Kiryat Weizman, Rehovot, Israel) was
incorporated into 1% agarose (FMC Corporation, Marine
Colloids Div., Rockland ,USA) containing 0,1% bovine
serum albumin, to permit slow release of the
leucoattractant and maintenance of a positive FMLP
gradient through the filters and dermis. FMLP was used
-6 -7 -8
at final concentrations of 10 M, 10 M and 10
-8 -7
M. Using in-vitro systems 10 M - 10 M
concentrations were found to be the optimum for PMNL
-6
migration and 10 M FMLP was supra-optimal. In 
control systems FMLP was omitted from the agarose. 
Cylindrical agarose Blocks +- FMLP (15 mm. diameter; 10 
mm. depth) were cut and placed onto the nitrocellulose 
filters (FIGURE 3f). For each FMLP-exposed system a 
corresponding, laterally-positioned FMLP-free control 
system was included to give a final arrangement of 1 
row of 4 control dermal zones and a parallel row of 4 
FMLP-exposed dermal zones. Individual areas of denuded 
dermis with superimposed filters and agarose blocks +- 
FMLP were then encased in transparent plexiglass cups 
(16 mm x 12 mm ) glued firmly to the skin. The filters 
and agarose blocks were replaced at 2 hour intervals up 
to 10 hours.
Filter processing for microscopic enumeration of 
PMNLs:- The nitrocellulose filters were removed and 
replaced at 2 hour intervals and placed in methanol for
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FIGURE 3: (a) A typical blister; (b) the zone of
exposed denuded dermis following the removal of 
epidermis, basement membrane and blister fluid; (c) the 
placement of the hollow adhesive ring reinforcer onto 
the dermis; (d) moistening of the dermis with HBSS; (e) 
the placement of the nitrocellulose filters onto the 
dermis; and (f) placement of agarose blocks +- FMLP 
onto the filters.
5 3
30 seconds to fix the PMNLs, rinsed in distilled H 0
2 2and stained in 1% haematoxylin for 1 minute, rinsed, 
dehydrated in ethanol and cleared in xylene and 
examined microscopically for PMNL accumulation. 
Enzymatic method for the measurement of PMNL 
accumulation:- Using this method the filters were 
placed into 0,8 ml of HBSS only (background control 
systems), or into 0,8 ml of HBSS containing 0,1 % 
triton-X 100, in 4,8 cm. x 1 cm. polypropylene test 
tubes. After 10 minutes the tubes were centrifuged at 
500XG for 10 minutes and the control supernatants and 
triton-X 100 lysates assayed for myeloperoxidase (MPO) 
and lysozyme content.
MPO assay:- Volumes of 200 micro litres of control 
supernatant or lysate were transferred to the wells of 
a microtitre tray and 50 micro litres of MPO substrate 
added to each well. The substrate was 0,3 % guaiacol 
(Sigma Chemical Co., St. Louis, Mo., USA) and 0,3 %
H^O^ in HBSS. Enzyme activity was measured 
spectrophotometrically in a Titertek R multiscan 
apparatus (Flow Laboratories Ltd.) at OD450 at 1 minute 
intervals and the OD450/minute calculated.
Lysozyme assay:- 50 micro litre of a 0,8% lysozyme 
substrate Micrococcus lysodeikticus (Sigma chemical 
Co.) in HBSS was added to 200 micro litre volume of 
filter supernatant or lysate in the wells of microtitre 
trays. The turbidity of the M. lysodeikticus was 
measured at OD450. Spectrophotometric readings at
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OD450 were recorded at time 0 and thereafter at 30 
minutes and 60 minutes. The lysozyme activity was 
measured as the decrease in turbidity of the bacterial 
suspension.
For both enzymes calibration curves were constructed
using horseradish peroxidase type VI (Sigma Chemical
Co.) and chicken egg white lysozyme grade 1. To relate
MPO and lysozyme activities directly to the PMNL
concentration on the filters, pure PMNLs were prepared
from blood specimens from normal adult volunteers as
previously described (Anderson and Van Rensburg, 1979).
6
The PMNLs at concentrations varying from 5 x 10 - l x  
8
10 /ml. were spotted onto pre-moistened nitrocellulose
5 6
filters in 20 micro litre volumes (1x10 - 2 x 10 PMNLs 
and transferred into HBSS +- triton-X 100 and the 
MPO and lysozyme concentrations in the lysates measured 
as above. Calibration curves were drawn of enzyme 
activity vs PMNL concentration.
Other investigations:- Histological examination of 
the detached epidermal blister roof and basement 
membrane from different volunteers and total and 
differential blood leucocyte counts were performed by 
the Departments of Histopathology and Haematology of 
the Institute for Pathology, University of Pretoria, 
respectively.
Results are presented on page 84.
55
THE EFFECTS OF ORAL ADMINISTRATION OF ERYTHROMYCIN ON
THE HUMAN IN-VIVO MIGRATION OF PMNLs USING THE ABOVE 
METHOD.
A single 500 mg. oral dose of erythromycin stearate or 
a matched placebo were administered to 4 pairs of age 
and sex-matched healthy adult human volunteers. The 
erythromycin and placebo tablets were coded and 
administered by an attendant clinician. Following the 
completion of blister formation as described previously 
(page 48) PMNL migration was then measured in 
erythromycin and placebo treated volunteers.
Results are shown in TABLE 15 (page 93).
EXPRESSION AND STATISTICAL ANALYSIS OF RESULTS.
The results are expressed as the mean value and 
standard error of the mean for each series of 
experiments. Statistical analyses were performed using 
the paired Students t test and Students t test for two 
means.
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RESULTS
CHAPTER III
THE DETERMINATION OF MIC AND MCC OF ERYTHROMYCIN FOR 
E. cloacae AND C. albicans.
As shown in TABLE 1 the MIC's and MCC's for E. cloacae 
and C. albicans were 3,0 mgm./ml. and >6,0 mgm./ml. 
respectively.
The method was as described on page 32.
RELATIONSHIP OF OD TO CFU.
FIGURES 4 and 5 show a linear OD/CFU relationship for 
E. cloacae and C. albicans within the CFU range used. 
The above graphs were used to convert the OD of 
E. cloacae and C. albicans to CFUs.
The method was as described on page 32.
THE EFFECTS OF ERYTHROMYCIN ON THE IN-VITRO GROWTH RATE
OF E. cloacae AND C. albicans IN THE PRESENCE OF
ERYTHROMYCIN USING A TURBIDOMETRIC METHOD.
TABLE 2 shows that there is no effect on C. albicans 
when co-incubated with erythromycin up to a 
concentration of 30,/ig./ml.
TABLE 3 shows that although E. cloacae was resistant to 
erythromycin, in a clinical sense, co-incubating 
E. cloacae with erythromycin at a concentration of 7,5' 
/ug./ml. retarded the growth rate of E. cloacae.
The method was as described on page 34.
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TABLE 1
THE DETERMINATION OF MIC AND MCC OF ERYTHROMYCIN FOR
E. cloacae AND C. albicans.
MIC MCC
E. cloacae 3,0 mgm./ml 3,0 mgm./ml.
C. albicans > 6,0 mgm./ml >6,0 mgm./ml.
The above results indicate that E. cloacae and especially 
C. albicans are resistant to erythromycin.
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FIGURE 4.
Demonstration of the linear CFU/OD relationship of 
E. cloacae.
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FIGURE 5.
Demonstration of the linear CFU/OD relationship of 
C. albicans.
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THE EFFECT OF ERYTHROMYCIN ON THE IN-VITRO GROWTH RATE 
OF E. cloacae IN THE PRESENCE OF ERYTHROMYCIN USING 
A TURBIDOMETRIC METHOD.
TABLE 2
OD OD OD
Time in- No 7,5/ug./ml. 30/ug./ml*
terval erythromycin erythromycin erythromycin 
18 hrs. 0,301 + -(.005)* 0,177+-(.002) 0,154 + - (. 006)
* Results are the mean value +- SEM of 3 assays.
61
TABLE3
THE EFFECT OF ERYTHROMYCIN ON THE IN-VITRO GROWTH RATE
OF C. albicans IN THE PRESENCE OF ERYTHROMYCIN USING A
TURBIDOMETRIC METHOD.
OD OD OD
NO 7,5/ug/ml. 30 y u g ./ml.
Time in- erythro- erythro- erythro-
tervals mycin mycin mycin
16 hrs. 0,047 +-.006 * 0,050 +-.001 0,056 +-.002
24 hrs. 0,072 +-.016 0,072 +-.005 0,084 +-.002
42 hrs. 0,333 +-.020 0,333 +-.021 0,331 +-.025
* Results are the mean values +- standard error of the
mean (SEM) of three assays.
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DETERMINATION OF THE QUANTITY OF ERYTHROMYCIN 
LACTOBIONATE IN THE PERITONEUM OF MICE AFTER 
INTRAPERITONEAL INOCULATION WITH ERYTHROMYCIN 
LACTOBIONATE.
TABLE 4 shows that the residual amount of erythromycin 
lactobionate present in the peritoneal wash (2 ml.) 60 
min. after a mouse has been inoculated with 0,5 ml. of 
a 3 mg./ml. of erythromycin lactobionate solution 
intraperitoneally, was less than 0,002 mg./ml. (volume 
of wash was taken into account).
Taking into consideration the results obtained in the 
investigation of the effects on the in-vitro growth of 
C. albicans in the presence of erythromycin (TABLE 3), 
one can assume that the erythromycin dose given to the 
mice prior to inoculation with C. albicans did not 
affect the C. albicans inoculum in a direct manner.
The method was as described on page 35.
DETERMINATION OF THE TOXICITY TO MICE OF ERYTHROMYCIN
LACTOBIONATE WHEN INOCULATED INTRAPERITONEALLY.
Intraperitoneal administration of erythromycin 
lactobionate at a concentration of up to 3 mgm. was not 
associated with toxic effects.
The method was as described on page 36.
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TABLE 4
DETERMINATION OF THE QUANTITY OF ERYTHROMYCIN
LACTOBIONATE IN THE PERITONEUM OF MICE AT DIFFERENT
TIME INTERVALS AFTER INTRAPERITONEAL INOCULATION OF
ERYTHROMYCIN LACTOBIONATE.
Peritoneal wash at Erythromycin lacto-
stated times bionate in the peri-
tonial wash.
mg./ml.
0 min. 0,425 +- 0,013 *
15 min. 0,01 +- 0,007
30 min. <0,001
60 min. <0,001
* Results are the mean values +- SEM of three 
determinations.
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DETERMINATION OF THE EFFECT OF BENZYL ALCOHOL ON THE
SURVIVAL RATE OF MICE INOCULATED WITH C. albicans.
FIGURE 6 shows that the presence of benzyl alcohol in 
erythromycin lactobionate did not influence the 
survival rate of mice inoculated with a lethal dose of 
C. albicans.
The method was as described on page 36.
THE EFFECTS OF INTRAPERITONEAL ADMINISTRATION OF 
ERYTHROMYCIN LACTOBIONATE ON THE SURVIVAL RATE OF MICE 
INOCULATED WITH A LETHAL INTRAPERITONEAL INOCULUM OF 
C. albicans.
FIGURES 7, 8 and 9 show a significant increase of the 
mean survival rate of mice pre-inoculated with 
erythromycin lactobionate relative to their controls 
inoculated with lactobionic acid.
Furthermore, FIGURE 9 shows a dose response curve to 
erythromycin lactobionate.
The method was that as described on page 37 .
65
20i
co
X
LUo
Q
LU
3
3UU<
16
12
8
4
HOURS
FIGURE 6: Determination of the effect of benzyl
alcohol on the survival rate of mice inoculated with a 
lethal dose of C. albicans.
Benzyl alcohol ( A ---- ▲ ) . PBS ( • ——  • ) .
Using students t Test for two means t = 0,33
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FIGURE 7: Mice inoculated intraperitoneally with
1 mg. of erythromycin and challenged with a LD50 
inoculum of C. albicans.
(A----A) erythromycin lactobionate.
(•--- •) lactobionic acid.
P < 0,005.
Using Students t Test for two means t = 3,37
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FIGURE 8: Mice inoculated intraperitoneally with
1 mg. of erythromycin and challenged with a LD100 
inoculum of C. albicans.
( ▲ ----▲) erythromycin lactobionate.
( • ----•) lactobionic acid.
P < 0,005.
Using Students t Test for two means t = 3,37
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HOURS
FIGURE 9: Mice inoculated intraperitoneally with
1 mg. and 0,5 mg. of erythromycin and challenged with a 
LD100 inoculum of C. albicans.
1  — -  I >
1,0 mg. erythromycin lactobionate.
( A --- A ) 0,5 mg. erythromycin lactobionate.
( • --------  • ) lactobionic acid.
Using Students t Test for two means:-
1,0 mg. erythromycin lactobionate t = 5,3; P < 0,005
0,5 mg. erythromycin lactobionate t = 4,0; P < 0,005
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THE EFFECTS OF INTRAVENOUS ADMINISTRATION OF
ERYTHROMYCIN LACTOBIONATE ON THE SURVIVAL RATE OF MICE 
INOCULATED WITH A LETHAL INTRAPERITONEAL INOCULUM OF 
C. ALBICANS.
FIGURES 10a, 10b, 10c, 10d and their statistical 
analysis shown in TABLE 5 show that the intravenous 
inoculation of 100 ^ ugm. erythromycin lactobionate 
causes a significant increase in the mean survival time 
of mice inoculated with a lethal intraperitoneal 
inoculum of C. albicans.
The method was as described on page 37.
MITOGEN-INDUCED TRANSFORMATIONS OF MOUSE SPLEEN
LYMPHOCYTES; MICE WERE PRE-INOCULATED INTRAPERITONEALLY
WITH 1 MG. OF ERYTHROMYCIN LACTOBIONATE 2 HOURS PRIOR
TO SACRIFICE.
TABLES 6 and 7 show that neither mitogen^ PHA nor COto-A 
enhanced the lymphocyte transformation of mouse spleen 
lymphocytes when erythromycin lactobionate was 
inoculated intraperitoneally.
The method was that as described on page 38.
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FIGURE 10a, 10b, 10c and 10d.
The effects of intravenous administration of 100/ugm. 
of erythromycin lactobionate on the survival rate of 
mice inoculated with a lethal intraperitoneal inoculum 
of C. albicans.
( A --- A) erythromycin lactobionate.
( • --- •) lactobionic acid.
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TABLE 5
STATISTICAL ANALYSIS OF
FIGURES 10a, 10b, 10c and 10d.
FIGURE 10a 10b 10c
Students t
Test for 1,9 2,5 2,99
two means
P values <0,05 <0,025 <0,005
10d
2,46
<0,01
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TABLE 6
PHA-INDUCED TRANSFORMATIONS OF MOUSE SPLEEN
LYMPHOCYTES; MICE WERE PRE-INOCULATED INTRAPERITONEALLY
WITH 1 MG. OF ERYTHROMYCIN LACTOBIONATE 2 HOURS PRIOR
TO SACRIFICE.
PHA Lacto- Eryth- t P
concen- bionic romycin value. value
tration, acid. lactobi-
micro onate.
gm./ml.
6 3998 +- 839 * 11230 +- 5596 1,629 >0,05
12 11381 +- 5397 18876 +- 1165 0,613 >0,05
25 23438 +- 10633 33180 +- 10804 0,841 >0,05
50 13487 +- 9244 21760 +- 11148 0,371 >0,05
100 6310 +- 5386 14862 +- 7171 - 0,962 >0,05
200 4850 -+- 4186 8890 +- 5264 .0,629 >0,05
400 2766 +- 2356 2892 +- 1057 0,056 >0,05
800 797 +- 387 628 +- 169 0,574 >0,05
BG 452 +- 135 420 +- 122 - -
BG = background.
* Results of TABLE 6 are shown as the means +- SEM 
of four sets of experiments.
t Value was obtained by using Students t Test for matched
groups.
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TABLE 7
CON-A INDUCED TRANSFORMATIONS OF MOUSE SPLEEN
LYMPHOCYTES; MICE WERE PRE-INOCULATED INTRAPERITONEALLY
WITH 1 MG. OF ERYTHROMYCIN LACTOBIONATE 2 HOURS PRIOR
TO SACRIFICE.
CON-A Lacto- Eryth- t P
concen- bionic romycin value. value.
tration acid lactobi-
micro onate
gm./ml.
6 399 +- 57 277 +- 20 0,592 >0,05
12 509 +- 215 750 +- 443 1,01 >0,05
25 522 +- 98 1160 +- 636 1,093 >0,05
50 830 +- 658 2914 +- 1558 1,355 >0,05
100 9258 +- 3923 6396 +- 3612 0,378 >0,05
200 16897 +- 7868 16918 +- 9221 0,002 >0,05
400 26246 +- 10905 29761 +- 11907 0,234 >0,05
800 3610 +- 1351 7137 +- 3609 0,810 >0,05
BG 400 +- 182 389 +- 172
BG = background.
* Results of TABLE 7 are shown as the means +- SEM 
of four sets of experiments.
t Value was obtained by using Students t Test for matched
groups.
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MITOGEN-INDUCED TRANSFORMATION OF MOUSE SPLEEN 
LYMPHOCYTES; MICE WERE PRE-INOCULATED INTRAVENOUSLY 
WITH 100/JGM OF ERYTHROMYCIN LACTOBIONATE 2 HOURS PRIOR 
TO SACRIFICE.
TABLES 8 and 9 show that there is a significant 
difference between the spleen lymphocyte 
transformations of mice pre-inoculated intravenously 
with erythromycin lactobionate and controls inoculated 
with lactobionic acid at the following mitogen 
concentrations.
PHA 6, 12, and 25/Ajgm./ml.
CON-A 100 /ugm./ml.
Method was as described on page 38.
EVALUATION OF THE AIR BLEB METHOD TO DETERMINE THE 
IN-VIVO MIGRATION RATE OF PMNLs GENERATED BY 
C. albicans.
Microscopic observations showed that the C. albicans 
inoculum did elicit a chemotactic infiltration of 
leucocytes into the membraneous lining of the bleb, the 
predominating infiltrating cells were microscopically 
determined as being PMNLs. It was observed however 
that the distribution of the leucocytes in the 
membranous lining of the bleb was irregular and the
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TABLE 8
PHA-INDUCED TRANSFORMATION OF MOUSE SPLEEN
LYMPHOCYTES; MICE WERE PRE-INOCULATED INTRAVENOUSLY
WITH 100/UGM. OF ERYTHROMYCIN LACTOBIONATE 2 HOURS
PRIOR TO SACRIFICE.
PHA Lacto- Eryth- t P
concen- bionic romycin value. value.
tration , acid. lactobi-
micro nate.
gm./ml.
6 606 +- 130 1413 +- 434 3,080 <0,05
12 6533 +- 4732 12304 +- 3712 2,581 <0,05
25 8304 +- 5296 19631 +- 6373 5,782 <0,01
150 4957 +- 3415 13366 +- 7869 1,885 >0,05
100 1615 +- 1032 7726 +- 6431 1,131 >0,05
200 610 +- 71 2617 +- 2273 0,888 >0,05
400 354 +- 45 436 +- 147 0,456 >0,05
800 321 +- 37 335 +- 68 - -
BG 319 +- 64 336 +- 130
BG =. Background.
Results are expressed as: the means +- SEM of four sets
of experiments.
t Value was obtained by using Students t Test for
matched groups.
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TABLE 9
CON-A INDUCED TRANSFORMATION OF MOUSE SPLEEN
LYMPHOCYTES; MICE WERE PRE-INOCULATED INTRAVENOUSLY
WITH 100/UGM. OF ERYTHROMYCIN LACTOBIONATE 2 HOURS
PRIOR TO SACRIFICE.
CON-A Lacto- Eryth- t p
concen- bionic romycin value. value.
tration acid. lactobi-
micro onate.
gm./ml.
6 408 +- 98 - -
12 740 + - 81 1171 +- 674 1,325 >0,05
25 2722 +- 265 2952 +- 1517 1,712 >0,05
50 5725 +- 1336 9564 +- 3864 2,092 >0,05
100 6709 +- 3880 11570 +- 5733 3,057 <0,05
200 1601 + - 4018 9504 +- 5265 2,183 >0,05
400 1136 +- 615 1343 +- 377 1,103 >0,05
800 - 429 +- 156 -
BG 298 +- 78 339 +- 136
BG = background.
Results are expressed as the means +- SEM of four sets
of experiments.
t Values were obtained by using Students t Test for
matched groups.
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concentrated areas appeared to be associated with 
adjacent arterioles or veinioles. The insurmountable 
difficulties encountered in trying to modify this 
method from a qualitative to a quantitative method 
caused its abandonment.
The method was as described on page 40 .
THE EFFECT ON THE RATE OF % PHAGOCYTIC UPTAKE BY
PMNLs OF C. albicans PREVIOUSLY EXPOSED TO
ERYTHROMYCIN.
TABLE 10 shows that growing C. albicans in the presence 
of erythromycin does not influence the % phagocytic 
uptake by PMNLs.
The method as described on page 42.
THE EFFECT OF ERYTHROMYCIN BASE ON INTRA-CELLULAR
KILLING OF YEASTS BY HUMAN PMNLs IN-VITRO.
Using the method as described on page 44, it was found 
that erythromycin base had no significant effect on the 
intracellular killing of yeasts by PMNLs.
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TABLE 10
THE EFFECT ON THE RATE OF % PHAGOCYTIC UPTAKE BY PMNL OF
C. albicans PREVIOUSLY EXPOSED TO ERYTHROMYCIN.
Times No Eryth. Eryth.
harves- eryth. 5,0 micro. 30,0 micro.
ted gm./ml. gm./ml.
% uptake % uptake % uptake
2 min. 48 +- 4* 41 +- 5 41 +- 6
5 min. 50 +- 5 48 +- 5 46 +- 5
15 min. 48 +- 4 48 +- 6 44 +- 4
* Results are expressed as the means +- SEM of six 
determinations.
79
THE EFFECT OF THE ADMINISTRATION OF A 500 MG. DOSE OF
ERYTHROMYCIN STEARATE ON MITOGEN INDUCED TRANSFORMATION
OF HUMAN LYMPHOCYTES CONTAINED IN WHOLE BLOOD.
TABLE 11 shows a significant increase in the PHA 
induced transformation between controls and tests of 
human peripheral lymphocytes at concentrations of 50 
and 25 yugm.
TABLE 12 shows no significant increase in the CON-A 
induced transformations between controls and tests.
The method was as described on page 45.
THE EFFECT OF THERAPEUTIC CONCENTRATIONS OF
ERYTHROMYCIN ON THE MIGRATION OF HUMAN PMNLs IN VITRO.
TABLE 13 shows that erythromycin base at concentrations 
of 3,5/ugm./ml. and greater caused a significant 
enhancement of PMNL migration to EAS.
The method was as described on page 46.
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TABLE 11
THE EFFECT OF THE ADMINISTRATION OF A 500 MG. DOSE OF
ERYTHROMYCIN STEARATE ON PHA INDUCED TRANSFORMATION OF
HUMAN LYMPHOCYTES CONTAINED IN WHOLE BLOOD.
Before After
PHA 
cone.
administration 
of erythromycin 
stearate.
administration 
of erythromycin 
stearate.
t
value.
P
value
BG 2180,0 +- 802,4 871,8 +- 245,0 1,91 >,05
100 27310,0 +- 3098,4 34121,3 +- 15259,4 1,58 >,05
50 34064,2 +- 15233,9 46728,3 +- 20897,5 r*-r—1 *CM <.05
25 35889,0 +- 6831,2 47126,8 +- 21075,7 3,40 <.01
3,1 18724,0 +- 8373,6 28931,8 +- 12938,7 1,46 >.05
PHA cone. = PHA Concentration in micro gm./ml.
BG = Background
The above results are the means, +- SEM, Students t 
test for matched groups and P values of 6 sets of 
experiments.
TABLE 12
THE EFFECT OF THE ADMINISTRATION OF A 500 MG. DOSE OF
ERYTHROMYCIN STEARATE ON CON-A INDUCED TRANSFORMATION OF
HUMAN LYMPHOCYTES CONTAINED IN WHOLE BLOOD.
Before After
administration administration
CON-A of erythromycin of erythromycin t P
cone. stearate • stearate! . value. value
BG 615,0 +- 355,1 716,3 +- 413,5 0.80 >,05
100 24429,0 +- 10925,0 19265,7 +- 8616,9 0,91 >,05
50 15097,7 +- 6752.0 11989,3 +- 5361,8 0,92 >.05
25 6833,7 +- 3056,1 5874,0 +- 2627,0 0,68 >,05
3,1 1157,0 +- 517,4 1059,7 +-- 474,0 0,47 >.05
CON-A cone. = CON-A concentration in micro gm./ml.
BG = Background
The above results are the means, +- SEM, Student t test for 
matched groups and P values of 6 sets of experiments.
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TABLE 13
THE EFFECT OF THERAPEUTIC CONCENTRATOR OF ERYTHROMYCIN
ON THE MIGRATION OF HUMAN PMNLS IN VITRO.
Percentage enhancement of PMNL chemotaxis to the
leucoattractant (endotoxin-activated serum) by
erythromycin.
Erythromycin Percentage stimulation
Concentration of PMNL migration.* P value.+
/ugm./ml.
3,5 22% <0,01
7,0 34% <0,01
17,5 52% <0.005
35,0 45% <0,025
* By comparison with the untreated control value. 
+ Paired Students '--statistics.
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THE FILTER BASED, ENZYMATIC METHOD FOR THE IN-VIVO
MEASUREMENT OF THE MIGRATION OF HUMAN POLYMORPHONUCLEAR 
LEUCOCYTES.
Skin blistering:- The initial attempts to form 
suitable blisters without using the manifold containing 
the valves to regulate blister formation, were 
unsuccessful because of asynchronous blister formation. 
The first blisters formed, either burst or formed 
intradermal haemorrhage while awaiting completion of 
the slower forming blisters. With the development and 
use of the manifold containing the valves, standardised 
blister formation could be attained.
Measurement of PMNL migration:- PMNL accumulation on 
the nitrocellulose filters was measured microscopically 
and enzymatically after 2, 4, 6, 8, and 10 hrs. 
Microscopic enumeration of stained PMNLs on processed 
filters was found to be quite unsuitable for 
quantitative studies due to the cell density on the 
lower side of the filter (in contact with the skin) and 
the irregular distribution of PMNLs on the upper and 
lower surfaces of the S^ Ajm. and 0,2/um. pore size 
filters respectively when the double filter system was 
used. Enzymatic measurement of MPO and lysozyme 
activities was however found to be objective and 
reproducible.
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Filter requirement:- In initial studies PMNL
accumulation on single 0,2/um. pore size filters was
compared with the double filter system using a lower
5 y«m. (in contact with the dermis) and an upper 0,2 yum.
pore size filter. These studies were performed on 3
different individuals with duplicate control and
FMLP-exposed blisters for both the single and double
filter systems per person. A single FMLP concentration 
6
of-10 M was used for these studies. Measurable 
PMNL accumulation occurred after 4 hrs. and was maximal 
at 6-10 hrs. Significantly greater PMNL accumulation 
was achieved using the double filter system especially 
with FMLP. This probably reflects the greater surface 
area available to the PMNL. These results for MPO are 
shown in FIGURE 11. Lysozyme results (not shown) were 
similar.
FMLP requirement:- The optimal FMLP concentration was
established using 3 different volunteers. Duplicate
areas of denuded dermis was exposed to agarose blocks
only (control system) or agarose blocks containing 8 7 6
—10 M,-10 m and-10 M FMLP respectively. The
double filter system was used and PMNL accumulation on
the filters measured after 2, 4, and 6 hrs. These
results for MPO after 6 hrs. are shown in FIGURE 12.
FMLP exposure promoted a dose dependent increase in
6
PMNL accumulation on the filters. — 10 M was found to 
be the optimal concentration of the leucoattractant.
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FIGURE 11. In the lower graph PMNL accumulation in 
control systems onto a single 0,2 ^ m. pore size
nitrocellulose filter (O-- O) or a combination of
0,2/um. and 5 /urn. pore size filters ( • — — • ) .  In the 
upper graph the corresponding results are shown for
FMLP-exposed systems using single (O-- O) and double
filters ( • ——— •). Results are expressed as the mean 
value +- SEM for 3 different individuals.
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FMLP CONCENTRATION (MOLAR)
FIGURE 12. PMNL accumulation, measured by MPO release, 
on double filters with various FMLP concentrations. 
These results were obtained 6 hrs. after blister 
induction and are expressed as the mean values +- SEM 
for 3 different individuals.
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Triton-X 100 requirement:- This was determined using 
—  — ---------------------------- ----------------- --------------------- — ------------  — 6
the double filter system and 10 M FMLP. Duplicate 
filters from control and FMLP-exposed areas of dermis 
were placed in HBSS only or HBSS containing 0,1% 
triton-X 100. After 15 min. incubation followed by 
centrifugation the supernatants were tested for MPO and 
lysozyme activities. These studies were performed on 3 
different individuals. The filters and agarose blocks 
were replaced after 2, 4, 6, 8 and 10 hrs. The results 
at 6 hrs. for MPO are shown in TABLE 14. Inclusion of 
triton-X 100 in HBSS markedly increased the activity of 
MPO and lysozyme (not shown). These findings 
demonstrate that the measurable enzyme activity in the 
triton-X 100 lysates is derived from PMNL on the 
filters of MPO and lysozyme released during cell 
migration.
Kinetics of PMNL migration:- Using the standardised
--------------------------------------------------  _ 6
method with double filters, 10 M FMLP and 1%
triton-X 100, PMNL accumulation was measured in 5
different individuals after 2, 4, 6, 8 and 10 hrs.
using 4 control and 4 FMLP-exposed areas of denuded
dermis per person. The results are shown in FIGURE 13.
Measurable PMNL migration occurred at 4 hrs. and was
maximal at 6-10 hrs. Significantly greater PMNL
accumulation was observed at each time interval in the
FMLP-exposed systems ( P<0,05-P<0,005 ). Staining of
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TABLE 14
INVESTIGATION OF THE REQUIREMENT FOR TRITON-X 100 TO
DETECT PMNL ACCUMULATION,
MPO activity
Control filters
T ime Without With
hr s. triton-X
100
triton-X
100
4 0 0,021+-0.005*
6 0 0,031+-0.006
* Results are the mean values
in
FMLP-exposed filters
Without With
triton-X triton-X
100 100
0.011+-0,004 0,054+-0,007
0,012 + -0,004 0, 061+-0,006
+- SEM for 3 different
individuals expressed as OD/min.
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FIGURE 13. Kinetics of PMNL accumulation on double 
filters according to MPO (upper graph) or lysozyme
-6
(lower graph) release for control (O-- O) and 10 M
FMLP-exposed systems ( • --- • ) . Results are
expressed as the mean value +- SEM for 5 different 
individuals.
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the filters revealed a predominantly PMNL infiltrate 
which was greater than 90% at each time interval for 
both control and FMLP-exposed systems.
The mean variability +- SEM between quadruplicate 
blisters was 26 +- 3% and 32 +- 3% with MPO and 
22 +- 2% and 32 +- 3% with lysozyme for FMLP-exposed 
and control systems respectively at 6 hrs. for 7 
different individuals.
Conversion of enzyme activities to cell numbers:-
Using the standard curve the enzymatic activities in
6 6
FIGURE 13 correspond to 3,3 X 10 , 4,2 X 10 ,
6 6
4,7 X 10 and 5,1 X 10 PMNLs at 4, 6, 8 and 10
hrs. respectively for FMLP systems. The corresponding
6 6
figures for control systems are 2,8 X 10 , 3,7 X 10 
6
and 3,6 X 10 PMNLs respectively.
Variability of PMNL MPO and lysozyme content:- The
mean MPO and lysozyme contents of PMNLs from 8
different individuals was 112,5 +- 4,2 units and 368,1
7
+- 12,8 units/10 PMNLs respectively. These results 
indicate very slight variability in MPO and lysozyme 
contents of PMNLs from different individuals.
Other investigations:- All of the volunteers used in
this study had normal white blood cell counts, 6,6 +- 
6
1,0 X 10 leucocytes per ml. of blood with 63 +- 3% 
polymorphonuclear leucocytes. Histopathological 
analysis of the blisters showed that blistering occurred
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at the epidermal-dermal junction. The blisters healed 
quickly without scarring leaving only faint 
dyspigmentation as described by Helium and Solberg 
(1977) .
THE EFFECTS OF ORAL ADMINISTRATION OF ERYTHROMYCIN ON
THE IN-VIVO MIGRATION OF HUMAN PMNLs.
TABLE 15 shows that the oral administration of 
erythromycin causes a significant enhancement of PMNL 
accumulation, however these studies should be extended 
to include more volunteers.
The method was as described on page 56.
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TABLE 15
THE EFFECTS OF ORAL ADMINISTRATION OF ERYTHROMYCIN ON
THE IN-VIVO MIGRATION OF PMNLs.
Matched pairs Myeloperoxidase Lysozyme
of human 
volunteers.
Placebo Test Placebo Test
1st set 0,262 0,346 0,018 0,111
2nd set 0,316 0,444 0,095 0,132
3rd set 0,381 0,402 0,027 0,068
4 th set ■ 0,362 0,390 0,162 0,160
Results are expressed as OD450 for MPO and 
Using Students t Test for matched groups:
lysozyme.
MPO t = 2,587 P = < ,05
Lysozyme t = 2,201 P = <,05
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DISCUSSION.
CHAPTER IV
DISCUSSION
Using a mouse model of non-specific immunostimulation 
as described by Gillisen (1982), erythromycin 
administration was found to increase the mean survival 
time of mice experimentally infected with C. albicans. 
These results were obtained irrespective of the route 
of administration of erythromycin (either 
intraperitoneally or intravenously). Stringent 
control systems excluded false positive results due to 
other components off the erythromycin preparation such 
as benzyl alcohol or lactobionic acid. Likewise the 
C. albicans strain used was absolutely insensitive to 
direct antimicrobial effects of erythromycin. Since 
similar results were obtained with intraperitoneal and 
intravenous administration of erythromycin, it is 
unlikely that the results of the intraperitoneal 
studies are due to a non-specific irritant effect 
leading to activation of peritoneal macrophages.
To identify possible targets of erythromycin mediated 
immunostimulation the effects of erythromycin 
administration on mitogen-induced lymphocyte 
proliferation and PMNL migration were investigated 
in-vivo. In-vitro investigation on the effects of 
erythromycin on migration and antimicrobial activity 
of PMNLs were also performed.
Pretreatment of PMNLs with erythromycin did not
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influence either phagocytic or antimicrobial activities 
in-vitro using C. albicans as the test micro-organism. 
Erythromycin does not therefore influence PMNL 
phagocytosis or intrinsic PMNL antimicrobial systems. 
The results of the mouse spleen lymphocyte 
transformations show that a 1 mg. dose of erythromycin 
lactobionate administered intraperitoneally caused a 
slight but statistically insignificant increase in 
mitogen induced lymphocyte transformation. However 100 
/ugm. of erythromycin lactobionate administered 
intravenously resulted in a statistically significant 
increase in lymphocyte proliferation. In an attempt to 
explain this phenomenon it is suggested that although 
the absorbtion of erythromycin from the peritoneal 
cavity is rapid erythromycin lactobionate has a more 
direct influence on lymphocytes when introduced 
intravenously. Enhancement of mitogen induced 
lymphocyte transformation during administration of 
erythromycin was also observed in human volunteers 
following administration of a single 500 mg. oral dose 
of the antibiotic. Roche et al. (1986) however 
reported that erythromycin inhibits mitogen (PHA and 
pokeweed mitogen) induced transformation in-vitro.
These results are in accordance with the observations 
of Anderson et al. (1982), who reported that 
erythromycin at concentrations of up to 35 /Ugm./ml. had 
no significant effect on lymphocyte transformation to
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CON-A and PHA in-vitro, but a progressive dose
dependent inhibition was observed with concentrations 
of erythromycin greater than 35/ugm./ml. These 
in-vitro/in-vivo discrepancies are not without 
precedence, since acetylspiramycin has been shown to 
depress macrophage phagocytosis in-vitro but enhances 
macrophage phagocytosis in-vivo (Si-Ying Li and 
Nelson 1985) . Likewise ketoconazole chemotherapy 
improves mitogen induced lymphocyte proliferation but 
causes inhibition in-vitro (van Rensburg et al. 1983). 
Erythromycin mediated potentiation of lymphocyte 
transformation could be due to inhibition of 
prostaglandin (PG) E2 synthesis. PG E2 a naturally 
occurring prostaglandin is a product of arachidonic acid 
a cell membrane phospholipid. Inhibition of PG E2 
release from stimulated lymphocytes by erythromycin 
possibly acting as an inhibitor of PG synthetase may be 
the mechanism responsible for the erythromycin-mediated 
increased lymphocyte transformation (Anderson et al. 
1984). Fox et al. (1982) suggest that erythromycin 
possesses anti-inflammatory properties. This may be 
due to the inhibitory effects of erythromycin on PG E2 
release by leucocytes (Anderson et al. 1984).
An alternative mechanism has been described by 
Becker et al. (1974) who suggest that erythromycin 
protects leucocytes from oxidative damage
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mediated by the MPO/H 0 /halide system which is
2 2activated within monocytes and macrophages during 
exposure to leucoattractants (Anderson et al. 1982).
To study the effect of erythromycin on PMNL migration 
both in-vitro and in-vivo methods were used.
The mouse air bleb method was discarded because of 
insurmountable difficulties associated in 
converting this test into a quantitative test. Since 
no suitable mouse methods were available to 
measure leucocyte migration, the investigation for the 
cause of the increased survival rate of mice pretreated 
with erythromycin and subsequently challenged with a 
lethal dose of C. albicans was directed to the effects 
of erythromycin on human PMNLs in both in-vitro and 
in-vivo conditions. In-vitro investigations showed 
that human PMNLs co-incubated with therapeutic 
concentrations of erythromycin in-vivo migrated in 
significantly greater numbers towards the chemotactic 
stimulus, endotoxin-activated autologous serum (EAS), 
relative to untreated control PMNLs. To measure 
leucocyte migration in-vivo. a modified suction- 
blistering technique (Helium and Solberg 1977) was 
developed. It was found that the insertion of control 
valves into the suction device facilitated the 
synchronisation and standardisation of blister 
formation. When the blisters had formed, usually after 
105 minutes, the raised epidermis, basement membrane
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and blister fluid were removed to expose the 8 
different areas of denuded dermis. Subsequent 
modifications were aimed at the development of an 
objective, sensitive and reproducible method of 
quantitating PMNL migration into the zones of denuded 
dermis. A method was devised using moistened 
nitrocellulose filters placed onto the areas of denuded 
dermis and overlaid with cylindrical blocks of 1% 
agarose containing the leucoattractant FMLP. In 
control systems FMLP-free agarose blocks were used. 
Incorporation of the FMLP into agarose had a number of 
probable advantages such as the maintenance of a 
positive FMLP gradient and protection of the FMLP from 
tissue and leucocyte proteases. Furthermore the 
pressure of the blocks and moisturising properties of 
the agarose promoted contact between the nitrocellulose 
filters and dermis.
As expected microscopic enumeration of PMNLs on the 
filters was found to be unsuitable for quantitative 
studies due to the density and irregular distribution 
of PMNLs on the filters. However enzymatic methods 
were found to be ideally suited to the measurement of 
PMNL accumulation on the filters. Filter-adherent 
PMNLs were disrupted by a 10 minute exposure to 
triton-X 100 and MPO and lysozyme activities in the 
lysates measured colourimetrically and turbidomet- 
rically respectively. Conversion of enzyme
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activities to absolute cell numbers was
accomplished using appropriate calibration curves.
The results of standardisation studies revealed that
maximal PMNL accumulation was detected using a double
-6filter system and an FMLP concentration of 10 M.
The double filter system with lower and upper filters
of 5 microns and 0,2 micron porosities respectively
presents a larger surface area for PMNL accumulation
than the single 0,2 micron pore size, PMNL
-6
impregnable filter. The optimal 10 M FMLP 
concentration is 10 - 100 fold greater than the 
corresponding in-vitro optimal concentrations. This 
probably reflects the requirement of a high 
concentration of FMLP due to the slow diffusion out of 
the agarose and through the filters.
Using this standardised method it was observed that 
measureable PMNL accumulation occurred at 4 hours and 
was maximal at 6 - 10 hours. These studies were not 
extended beyond 10 hours. Significantly greater PMNL 
accumulation occurred in FMLP exposed systems at 4 - 10 
hours. It must be emphasized that easily detectable 
PMNL accumulation was also observed in control systems, 
probably, due to the release of a variety of different 
leucoattractants derived from arachidonic acid 
metabolism and proteolytic cleavage of the third and 
fifth complement components during the induction of 
tissue injury by the suction blistering process. The
99
inclusion of FMLP increased the intensity of the 
leucotactic stimulus and amplified PMNL migration.
To date this method has only been applied to the 
measurement of PMNL migration in healthy adult 
volunteers. However it is likely that it could be 
modified to measure monocyte accumulation by 
extending the time (10 hours and beyond) and using a 
monocyte-specific marker to quantitate these cells on 
the filters. This could be achieved using a 
monocyte-specific extractable enzyme such as an 
esterase detectable by colourimetric analyses or by 
using radiolabelled or enzyme-linked monoclonal 
antibodies to monocyte specific antigens.
There are many possible immunological and 
immunopharmacological applications of this method. It 
could be used to evaluate the in-vivo significance of 
abnormalities of PMNL migration detected in-vitro as 
well as the in-vivo response of abnormal PMNL migration 
to the administration of agents which stimulate PMNL 
migration in-vitro. At present no suitable human model 
exists to investigate the effects of antibiotics and 
other pharmacological agents on PMNL movement in-vivo. 
The improved, objective method for the in-vivo 
measurement of PMNL migration is uncomplicated by the 
removal of PMNLs from their natural environment and by 
the trauma of cell processing procedures.
This filter based in-vivo method was applied to
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on PMNL migration and showed that therapeutic doses of
erythromycin increase the in-vivo migration of PMNLs
in adult humans. These investigations should be
extended to include more volunteers and to confirm
the role PMNLs play in the active transport of
erythromycin to sites of bacterial infection.
Mechanisms ascribed to potentiation of PMNL migration
are the same as those causing potentiation of
lymphocyte transformation, namely erythromycin
inhibition of PG E2 release and inhibition of
auto-oxidation mediated by the MPO/H 0 /halide system
2 2
activated during exposure to leucoattractants as 
described previously.
In conclusion it has been shown that erythromycin is 
responsible for the potentiation of both lymphocyte 
transformation and PMNL migration in-vivo and in-vitro, 
resulting in an enhanced immune defence mechanism. It 
is suggested that this augmentation of the immune 
defence mechanism by erythromycin increased the mean 
survival time of mice inoculated with a lethal dose of 
C. albicans. The enhancement of host immune-defences by 
erythromycin during treatment of an infection may 
contribute to the ultimate eradicatiion of target 
microbial pathogens.
determine the effect of administration of erythromycin
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